

*IN VIVO* EFFECT OF *EPILOBIUM HIRSUTUM* L. AND *VISCUM ALBUM* L. ON  
PROTEIN AND mRNA EXPRESSIONS OF RAT LIVER VITAMIN D<sub>3</sub>  
METABOLIZING CYP24A1 AND CYP27B1 ENZYMES

A THESIS SUBMITTED TO  
THE GRADUATE SCHOOL OF NATURAL AND APPLIED SCIENCES  
OF  
MIDDLE EAST TECHNICAL UNIVERSITY

BY

MELİKE SEVER

IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR  
THE DEGREE OF MASTER OF SCIENCES  
IN  
BIOCHEMISTRY

SEPTEMBER 2012

Approval of the Thesis

**IN VIVO EFFECT OF *EPILOBIUM HIRSUTUM* L. AND *VISCUM ALBUM* L. ON  
PROTEIN AND mRNA EXPRESSIONS OF RAT LIVER VITAMIN D3  
METABOLIZING CYP24A1 AND CYP27B1 ENZYMES**

submitted by **Melike SEVER** in partial fulfillment of the requirements for the degree of  
the degree of **Master of Science in Biochemistry Department, Middle East Technical  
University** by,

Prof. Dr. Canan ÖZGEN  
Dean, Graduate School of **Natural and Applied Sciences**

Prof. Dr. Candan GÜRAKAN  
Head of Department, **Biochemistry**

Prof. Dr. Orhan ADALI  
Supervisor, **Biology Dept., METU**

Prof. Dr. Alaattin ŞEN  
Co-Supervisor, **Biology Dept. Pamukkale University**

**Examining Committee Members:**

Prof. Dr. Musa DOĞAN  
**Biology Dept., METU**

Prof. Dr. Orhan ADALI  
**Biology Dept., METU**

Prof. Dr. Alaattin ŞEN  
**Biology Dept., Pamukkale University**

Prof. Dr. İrfan KANDEMİR  
**Biology Dept., Ankara University**

Assoc. Prof. Dr. Ewa JAKUBOWSKA-DOĞRU  
**Biology Dept., METU**

**Date:** 13.09.2012

**I hereby declare that all information in this document has been obtained and presented in accordance with academic rules and ethical conduct. I also declare that, as required by these rules and conduct, I have fully cited and referenced all material and results that are not original to this work.**

Name, Last Name: Melike Sever

Signature:

## ABSTRACT

### ***IN VIVO* EFFECT OF *EPILOBIUM HIRSUTUM* L. AND *VISCUM ALBUM* L. ON PROTEIN AND mRNA EXPRESSIONS OF RAT LIVER VITAMIN D<sub>3</sub> METABOLIZING CYP24A1 AND CYP27B1 ENZYMES**

Sever, Melike

M.Sc., Department of Biochemistry

Supervisor: Prof. Dr. Orhan Adalı

Co-Supervisor: Prof. Dr. Alaattin Şen

September 2012, 109 pages

*Epilobium hirsutum* L. (Onagraceae) is a flowering, tall and perennial plant and native to Eurasia. It shows analgesic, anti-microbial and anti-proliferative activity, and it is used in our country as an alternative medicine. The pharmacological effect of *Epilobium hirsutum* L. could be explained by the presence of polyphenolics including steroids, tannins and flavonoids in the aerial parts. *Viscum album* L. (Loranthaceae) is a shrub that grows as an epiphyte on the branches of deciduous trees. It involves in the enhancement of macrophage phagocytic and cytotoxic mediated abilities as well as the strengthening the immune system.

CYP24A1 and CYP27B1 are members of cytochrome P450 superfamily and the most important enzymes involved in the metabolism of vitamin D<sub>3</sub>. CYP27B1 and CYP24A1 are mitochondrial enzymes and also known as 25-hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase and 24-hydroxylase, respectively. CYP24A1 involves in 24-hydroxylation of 25-OH-D<sub>3</sub> and 1,25-(OH)<sub>2</sub>D<sub>3</sub> which is required for the catabolism of vitamin D<sub>3</sub>

compounds while CYP27B1 involves in 1 $\alpha$ -hydroxylation of 25-OH-D<sub>3</sub> into 1,25-(OH)<sub>2</sub>D<sub>3</sub>.

In this study, *in vivo* effects of *Epilobium hirsutum* and *Viscum album* (subspecies growing on pine-trees-subsp. *austriacum* (Wiesb.) Vollmann) on rat liver CYP24A1 and CYP27B1 mRNA and protein expressions were investigated. To achieve this goal, 37.5 mg water extract of *Epilobium hirsutum* L./kg body weight/day was intraperitoneally injected to male rats for 9 days. To study the effect of *Viscum album* L., 10 mg water extract of *Viscum album* L./kg body weight/day was injected with the same conditions. After decapitation, livers were removed and S1.5 fractions were prepared. Effects of *Epilobium hirsutum* L. and *Viscum album* L. on rat liver mRNA and protein expressions were analyzed by qRT-PCR and western blotting, respectively.

*Epilobium hirsutum* L. extract caused 31% and 18% decrease in rat liver CYP24A1 (p<0.0001) and CYP27B1 (p<0.05) protein expressions, respectively. The effect of *Epilobium hirsutum* L. on mRNA expression of CYP24A1 could not be observed, because CYP24A1 mRNA was almost undetectable in liver. Injection of *Epilobium hirsutum* L. to rats caused 2.7 fold increase in mRNA expression of CYP27B1 with respect to controls and normalized with GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) expression as an internal reference (p<0.005).

*Viscum album* L. caused 17% decrease in CYP24A1 protein expression (p<0.05). When rats injected with plant extract of *Viscum album* L., 18% decrease in CYP27B1 protein expression was observed (p<0.05). The effect of *Viscum album* L. on mRNA expression of CYP24A1 could not be observed since CYP24A1 mRNA was almost undetectable in liver. Injection of *Viscum album* L. to rats caused 3.8 fold increase in mRNA expression of CYP27B1 with respect to controls and normalized with GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) expression as an internal reference (p<0.005).

In conclusion, vitamin D<sub>3</sub> metabolism may be affected by medicinal plants *Epilobium hirsutum* L. and *Viscum album* L. due to the changes in mRNA and protein expressions of CYP24A1 and CYP27B1 enzymes.

**Key words:** *Epilobium hirsutum* L., *Viscum album* L., Vitamin D<sub>3</sub>, CYP24A1, CYP27B1, mRNA and protein expression, rat liver

## ÖZ

### ***EPILOBIUM HIRSUTUM L. VE VISCUM ALBUM L.*'NİN SIÇAN KARACİĞER VİTAMİN D<sub>3</sub> METABOLİZMASINDA ROL ALAN CYP24A1 VE CYP27B1 ENZİMLERİNİN PROTEİN VE mRNA EKSPRESYONU ÜZERİNDEKİ *İN VİVO* ETKİLERİ**

Sever, Melike

Yüksek Lisans, Biyokimya Bölümü

Tez Yöneticisi: Prof. Dr. Orhan Adalı

Ortak Tez Yöneticisi: Prof. Dr. Alaattin Şen

Eylül 2012, 109 sayfa

*Epilobium hirsutum L.* Avrasya'ya özgü, tıbbi bitki olarak kabul edilen ve Türkiye'de tüylü yakı otu olarak bilinen çok yıllık bir bitkidir. Analjezik, anti-mikrobiyal ve antiproliferatif etkilere sahiptir. İçerdiği polifenoller sayesinde çeşitli farmakolojik etkilere sahip olduğu için birçok hastalığın tedavisinde ve önlenmesinde etkili olduğu düşünülmektedir. *Viscum album L.* ise aynı şekilde alternatif tıpta kullanılan ve Türkiye'de ökse otu olarak bilinen çalı türüdür. Makrofajların fagositik ve sitotoksik etkilerinin genişletilmesinde etkili olduğu gibi bağışıklık sisteminin güçlendirilmesinde de rol almaktadır. Ayrıca, steril ekstraktları kanser tedavisinde kullanılmaktadır.

CYP24A1 ve CYP27B1, sitokrom P450 enzimleri arasında yer alıp vitamin D<sub>3</sub> metabolizmasında görev yapan en önemli enzimlerdendir. CYP24A1 ve CYP27B1

enzimlerinin ikisi de mitokondriyal enzimler olup birçok organda bulunmaktadır. CYP24A1 enzimi vitamin D bileşiklerinin inaktivasyonunda yer alır. 25-OH-D<sub>3</sub> ve 1,25-(OH)<sub>2</sub>D<sub>3</sub> moleküllerinin 24-hidroksilasyonunu katalizlediği için 24-hidroksilaz enzimi olarak da bilinir. CYP27B1 ise esas olarak vitamin D aktivasyonunda görev yapar. 25-OH-D<sub>3</sub> molekülünün 1 $\alpha$ -hidroksilasyonunu katalizlediği için 1 $\alpha$ -hidroksilaz enzimi olarak da bilinir.

Bu çalışmada *Epilobium hirsutum* L. ve *Viscum album* L. (çam ağaçları üzerinde yetişen alt türü-subsp. *austriacum* (Wiesb.) Vollmann) bitkilerinin sıçan karaciğer CYP24A1 ve CYP27B1 mRNA ve protein ekspresyonları üzerine *in vivo* etkileri araştırılmıştır. Bunun için, *Epilobium hirsutum*'un 18.75mg sulu ekstraktı wistar albino sıçanlara 9 gün boyunca intraperitoneal olarak enjekte edilmiştir. *Viscum album* içinse bu miktar 10 mg olarak belirlenmiştir. 11 tane sıçan ise kontrol olarak kullanılmıştır. Daha sonra, sıçanlar dekapite edilerek karaciğerleri çıkarılmış ve S1.5 fraksiyonlar elde edilmiştir. mRNA ekspresyonu tayini, kantitatif gerçek zamanlı PZR kullanılarak, protein ekspresyonu tayini ise "Western blot" tekniği ile elde edilmiştir.

Deneyler sonucunda *Epilobium hirsutum* L. bitkisinin sulu ekstraktının CYP24A1 protein ekspresyonunu %31 azalttığı gözlemlenmiştir (p<0.0001). Ayrıca, *Epilobium hirsutum* L., CYP27B1 protein ekspresyonunu %18 azaltmıştır (p<0.05). CYP24A1 mRNA ekspresyonunun karaciğerde saptanması zor olduğu için, bu bitkinin CYP24A1 mRNA ekspresyonu üzerine etkileri deneysel olarak gösterilemezken, *Epilobium hirsutum* L.'in CYP27B1 mRNA ekspresyonunu kontrollere göre 2.7 kat arttırdığı bulunmuştur (p<0.005).

Aynı şekilde *Viscum album* L. bitkisinin sulu ekstraktı CYP24A1 ve CYP27B1 protein ve mRNA ekspresyonlarını etkilemiştir. *Viscum album* L. CYP24A1 protein ekspresyonunu %17 azaltmıştır (p<0.05). Ayrıca, *Viscum album* L.'in CYP27B1 protein ekspresyonunu %18 azalttığı bulunmuştur (p<0.05). CYP24A1 mRNA ekspresyonunun karaciğerde saptanması zor olduğu için, bu bitkinin CYP24A1 mRNA ekspresyonu



üzerine etkileri deneysel olarak gösterilemezken, *Viscum album* L. CYP27B1 mRNA ekspresyonunu kontrollere göre 3.8 kat arttırdığı gözlemlenmiştir ( $p<0.005$ ).

Sonuç olarak, *Epilobium hirsutum* L. ve *Viscum album* L. tıbbi bitkilerinin CYP24A1 ve CYP27B1 ekspresyonunu değiştirebilmekte ve dolayısıyla vitamin D<sub>3</sub> metabolizmasını etkilemektedir.

**Anahtar kelimeler:** *Epilobium hirsutum* L., *Viscum album* L., vitamin D<sub>3</sub>, CYP24A1, CYP27B1, mRNA and protein ekspresyonu, sıçan karaciğeri

**To My Family,**

*For their endless support and love*

## ACKNOWLEDGEMENTS

I am deeply grateful to my supervisor Prof. Dr. Orhan Adalı for his valuable guidance, patient, continued advice and critical discussion throughout this study.

I am also deeply grateful to my co-supervisor Prof. Dr. Alaattin Şen for her guidance and advices throughout this study.

I thank to my examining committee members Prof. Dr. Musa Doğan, Prof. Dr. İrfan Kandemir and Assoc. Prof. Dr. Ewa Jakubowska-Doğru for their suggestions and criticism.

I also thank to Assoc. Prof. Dr. Ayşe Mine Gençler-Özkan for the cooperation in the study.

I am grateful to Serdar Karakurt for sharing his knowledge and experience with me; I learned a lot from him before and throughout this study. I also thank to my lab mates Dr. Aysun Türkanoğlu Özçelik, Dr. Çiğdem Gökçek Saraç, Tuba Çulcu, Ezgi Eroğlu, Yağmur Miçooğullari, Bora Ergin and Emre Evin for their beautiful friendship and support.

I especially thank to Hasan Ufuk Çelebioğlu for his endless friendship, help and support.

I wish to thank to The Scientific and Technological Research Council of Turkey (TÜBİTAK) for financial support.

I am thankful to Neşe Çakmak, İhsan Cihan Ayanoğlu, İsmail Cem Yılmaz, İbrahim Alper Ozan, Oya Tekeşin, Ahu Durmuşçelebi and İlknur Akbulut for their friendships.

I thank to Muzaffer Eryılmaz and Behiye Eryılmaz for their endless support.

I also would like to send my warmest thanks to Oytun Bahçekapılı for his support and love.

This study is dedicated to my family, whose help, advice, patience, support, and love are undeniable and unforgettable. Without them I couldn't have done this. Thank you for everything.

# TABLE OF CONTENT

ABSTRACT .....	iv
ÖZ .....	vii
ACKNOWLEDGEMENTS .....	xi
TABLE OF CONTENT .....	xiii
LIST OF TABLES .....	xvii
LIST OF FIGURES .....	xviii
LIST OF SYMBOLS AND ABBREVIATIONS .....	xxii
CHAPTERS	
1. INTRODUCTION .....	1
1.1. <i>Epilobium hirsutum</i> L.....	2
1.2. <i>Viscum album</i> L.....	5
1.3. Vitamin D <sub>3</sub> and its metabolism .....	9
1.3.1. Introduction.....	9
1.3.2. Vitamin D <sub>3</sub> metabolism.....	11

1.3.2.1.	25-hydroxylation.....	13
1.3.2.2.	1 $\alpha$ -hydroxylation.....	14
1.3.2.3.	24-hydroxylation.....	14
1.3.3.	Factors affecting the vitamin D <sub>3</sub> metabolism.....	15
1.3.4.	Biological actions of 1,25(OH) <sub>2</sub> D <sub>3</sub> .....	16
1.4.	Cytochrome P450s .....	18
1.4.1.	Introduction.....	18
1.4.2.	Nomenclature .....	18
1.4.3.	Mechanism .....	19
1.4.4.	Tissue distribution and function.....	21
1.4.5.	Cytochrome P45024A1 (CYP24A1) .....	23
1.4.6.	Cytochrome P45027B1 (CYP27B1).....	26
1.5.	Aim of the study .....	27
2.	MATERIALS & METHODS .....	29
2.1.	Materials.....	29
2.2.	Methods .....	30
2.2.1.	Collection of the plants and extraction procedure.....	30
2.2.2.	Animal Studies.....	31

2.2.3.	Preparation of Rat Liver S1.5 Fraction .....	32
2.2.4.	Determination of Protein Concentrations.....	33
2.2.5.	Determination of protein expression.....	36
2.2.5.1.	Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) .....	36
2.2.5.2.	Western blotting.....	40
2.2.6.	Determination of mRNA expression.....	44
2.2.6.1.	Isolation of total RNA from rat liver tissues.....	44
2.2.6.2.	Determination of RNA concentration.....	45
2.2.6.3.	Qualification of RNA molecules by agarose gel electrophoresis .....	46
2.2.6.4.	cDNA synthesis .....	46
2.2.6.5.	Quantitative real-time PCR.....	47
2.2.7.	Statistical Analysis .....	50
3.	RESULTS .....	51
3.1.	Protein concentrations of rat liver S1.5 fractions .....	51
3.2.	Effects of <i>Epilobium hirsutum</i> L. on CYP24A1 and CYP27B1 protein expression .....	52
3.2.1.	Effect of <i>Epilobium hirsutum</i> L. on CYP24A1 protein expression .....	52
3.2.2.	Effect of <i>Epilobium hirsutum</i> L. on CYP27B1 protein expression .....	54

3.3. Effect of <i>Epilobium hirsutum</i> L. on CYP24A1 and CYP27B1 mRNA expression .....	57
3.3.1. Quality control of RNA molecules by agarose gel electrophoresis .....	57
3.3.2. Effect of <i>Epilobium hirsutum</i> L. on CYP24A1 mRNA expression .....	59
3.3.3. Effect of <i>Epilobium hirsutum</i> L. on CYP27B1 mRNA expression .....	61
3.4. Effect of <i>Viscum album</i> L. on CYP24A1 and CYP27B1 protein expression ...	66
3.4.1. Effect of <i>Viscum album</i> L. on CYP24A1 protein expression .....	66
3.4.2. Effect of <i>Viscum album</i> L. on CYP27B1 protein expression .....	68
3.5. Effect of <i>Viscum album</i> L. on CYP24A1 and CYP27B1 mRNA expression ...	70
3.5.1. Quality control of RNA molecules by agarose gel electrophoresis .....	70
3.5.2. Effect of <i>Viscum album</i> L. on CYP24A1 mRNA expression .....	71
3.5.3. Effect of <i>Viscum album</i> L. on CYP27B1 mRNA expression .....	73
4. DISCUSSION .....	79
5. CONCLUSION .....	86
REFERENCES.....	88
APPENDIX	
A. APPROVALS OBTAINED FROM ETHICAL COMMITTEE .....	106



## LIST OF TABLES

### TABLES

Table 1. 1 Human cytochrome P450 genes .....	22
Table 2. 1 The reaction mixture of tubes prepared for determination of protein concentrations.....	35
Table 2. 2 Constituents of separating and stacking gel solutions. ....	37
Table 2. 3 Primer sequences, annealing temperatures and product sizes.....	49
Table 3. 1 Average protein concentrations of rat liver S1.5 fractions .....	51
Table 3. 2 The Livak ( $2^{-\Delta\Delta ct}$ ) method for the calculation of relative mRNA expression using Ct values. ....	64
Table 3. 3 The Livak ( $2^{-\Delta\Delta ct}$ ) method for the calculation of relative mRNA expression using Ct values. ....	77
Table 4. 1 Summary of the results. ....	81

## LIST OF FIGURES

### FIGURES

Figure 1. 1 <i>Epilobium hirsutum</i> L. ....	3
Figure 1. 2 <i>Viscum album</i> L. ....	6
Figure 1. 3 Nutritional forms of vitamin D.....	10
Figure 1. 4 Chemistry and irradiation pathway for production of vitamin D <sub>3</sub> .....	11
Figure 1. 5 Pathways of vitamin D activation and inactivation .....	12
Figure 1. 6 Nomenclature of cytochromes P450.....	19
Figure 1. 7 Generalized cytochrome P450 catalytic cycle for the oxidation of substrates .....	20
Figure 1. 8 Crystal Structure of rat CYP24A1 with 1,25-(OH) <sub>2</sub> D <sub>3</sub> . ....	24
Figure 1. 9 Three-dimensional structure model of CYP27B1. ....	26
Figure 2. 1 Western Blots sandwich.....	42
Figure 2. 2 Detection in western blots .....	43
Figure 3. 1 Immunoreactive protein bands of control and <i>Epilobium hirsutum</i> L.-treated groups representing CYP24A1 and β actin.....	53
Figure 3. 2 <i>In-vivo</i> effect of <i>Epilobium hirsutum</i> L. on CYP24A1 protein expression. ...	54
Figure 3. 3 Immunoreactive protein bands of control and <i>Epilobium hirsutum</i> L.-treated groups representing CYP27B1 and β-actin.....	56

Figure 3. 4 <i>In-vivo</i> effect of <i>Epilobium hirsutum</i> L. on CYP27B1 protein expression. ...	57
Figure 3. 5 Agarose gel electrophoresis pattern of RNA samples isolated from rat liver tissues.....	58
Figure 3. 6 Melting curve showing the fluorescence of SYBR green dye I versus temperature with 55 °C as annealing temperature. ....	60
Figure 3. 7 Melting curve showing the fluorescence of SYBR green dye I versus temperature with 60 °C as annealing temperature. ....	60
Figure 3. 8 Standard curve derived from dilution series of a control cDNA to measure quantities of specific CYP27B1 mRNAs in the sample.....	61
Figure 3. 9 Amplification plot showing the changes in fluorescence of SYBR green dye I versus cycle number of rat liver CYP27B1 gene of control and <i>Epilobium hirsutum</i> -treated samples. ....	62
Figure 3. 10 Melting curve showing the fluorescence of SYBR green dye I versus temperature with one peak meaning single PCR product detection. ....	62
Figure 3. 11 qRT-PCR product of liver CYP27B1 cDNA (107bp) of control and <i>Epilobium hirsutum</i> -treated animals .....	63
Figure 3. 12 qRT-PCR product of liver GAPDH cDNA (240 bp) of control and <i>Epilobium hirsutum</i> -treated animals .....	64
Figure 3. 13 <i>In vivo</i> effect of <i>Epilobium hirsutum</i> L. on rat liver CYP27B1 mRNA expression.....	65
Figure 3. 14 Immunoreactive protein bands of control and <i>Viscum album</i> L.-treated groups representing CYP24A1 and $\beta$ -actin .....	67

Figure 3. 15 <i>In-vivo</i> effect of <i>Viscum album</i> L. on CYP24A1 protein expression. ....	68
Figure 3. 16 Immunoreactive protein bands of control and <i>Viscum album</i> L.-treated groups representing CYP27B1 and $\beta$ -actin.....	69
Figure 3. 17 <i>In-vivo</i> effect of <i>Viscum album</i> L. on CYP27B1 protein expression. ....	70
Figure 3. 18 Agarose gel electrophoresis pattern of RNA samples isolated from rat liver tissues.....	71
Figure 3. 19 Melting curve showing the fluorescence of SYBR green dye I versus temperature with 50 °C as annealing temperature. ....	72
Figure 3. 20 Melting curve showing the fluorescence of SYBR green dye I versus temperature with 60 °C as annealing temperature. ....	73
Figure 3. 21 Standard curve derived from dilution series of a control cDNA to measure quantities of specific CYP27B1 mRNAs in the sample.....	74
Figure 3. 22 Amplification plot showing the changes in fluorescence of SYBR green dye I versus cycle number of control and <i>Viscum album</i> -treated rat livers' CYP27B1 gene.	74
Figure 3. 23 Melting curve showing the fluorescence of SYBR green dye I versus temperature with one peak meaning single PCR product detection .....	75
Figure 3. 24 qRT-PCR product of control and <i>Viscum album</i> -treated rat livers' CYP27B1 cDNA.....	76
Figure 3. 25 qRT-PCR product of control and <i>Viscum album</i> -treated rat livers' GAPDH cDNA.. .....	77
Figure 3. 26 <i>In vivo</i> effect of <i>Viscum album</i> L. on rat liver CYP27B1 mRNA expression.....	78

Figure 4. 1 Schematic diagram of miRNA-mediated translational repression. ....83

## LIST OF SYMBOLS AND ABBREVIATIONS

<b>APS</b>	Ammonium per sulfate
<b>BCIP</b>	5-bromo 4-chloro 3-indoyl phosphate
<b>BSA</b>	Bovine serum albumin
<b>cAMP</b>	Cyclic adenosine monophosphate
<b>CaR</b>	Calcium-sensing receptor
<b>cDNA</b>	Complementary deoxyribonucleic acid
<b>Ct</b>	Threshold cycle
<b>CRE</b>	cAMP response element
<b>CYP</b>	Cytochrome P450
<b>DBP</b>	Vitamin D binding protein
<b>DEPC</b>	Diethylpyrocarbonate
<b>DNA</b>	Deoxyribonucleic acid
<b>dNTP</b>	Deoxynucleoside triphosphate
<b><math>\epsilon</math>-ACA</b>	$\epsilon$ -Amino caproic acid
<b>EDTA</b>	Ethylenediaminetetraacetic acid
<b>ERB</b>	Electrophoretic running buffer
<b>FAD</b>	Flavin adenine dinucleotide
<b>FGF-23</b>	Fibroblast growth factor 23
<b>FMN</b>	Flavin mononucleotide
<b>GAE</b>	Gallic acid equivalents
<b>i.p.</b>	intraperitoneal
<b>kDa</b>	kilo Dalton
<b><i>K<sub>m</sub></i></b>	Michaelis constant
<b>mRNA</b>	Messenger RNA
<b>NADH</b>	Nicotinamide adenine dinucleotide, reduced form
<b>NADPH</b>	Nicotinamide adenine dinucleotide phosphate, reduced form

<b>NBT</b>	Nitrotetrazolium blue chloride
<b>PCR</b>	Polymerase chain reaction
<b>PIP<sub>2</sub></b>	Phosphatidylinositol 4,5-bisphosphate
<b>PTH</b>	Parathyroid hormone
<b>rpm</b>	Revolutions per minute
<b>RNA</b>	Ribonucleic acid
<b>RXR</b>	Retinoic X receptor
<b>SDB</b>	Sample dilution buffer
<b>SDS</b>	Sodium dodecyl sulfate
<b>SDS-PAGE</b>	Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
<b>TBST</b>	Tris-buffered saline and Tween 20
<b>TEMED</b>	Tetramethylethylenediamine
<b>VDR</b>	Vitamin D receptor
<b>VDRE</b>	Vitamin D response element
<b>UV</b>	Ultraviolet

# CHAPTER 1

## INTRODUCTION

Plants have always been used in medicine throughout the history. At the beginning, plants were used as medicine in their raw forms such as teas, powders, poultices and other several herbal forms (Balick & Cox, 1996). The methods and formulations of these plants were transmitted orally, but then the informations were recorded. In recent history, the active compounds of these plants began to be isolated. Today, characterization of these active compounds in medicinal plants still continue. There are several important examples for the usage of these medicinal plants in drug discovery, which are introduced to the markets after important clinical trials. These plants have many serious properties such as antioxidant, anti-inflammatory, antimicrobial, anti-mutagenic characteristics. For instance, *Viscum album* L. and *Epilobium hirsutum* L. are known as important medicinal plants used in alternative medicine. *Epilobium hirsutum* L. is used as anti-inflammatory and edema preventer (Kiss *et al.*, 2011) while *Viscum album* L. has important role in the treatment of some cancers as well as cardiovascular diseases (Gupta *et al.*, 2012).

Medicinal plants have numerous phenolic and polyphenolic compounds which display important role in human health. These compounds may have effects on the modulation of enzymes responsible for the xenobiotic or endogen metabolism. Vitamin D<sub>3</sub>, one of the endogens metabolized in the body, mainly involves in maintenance of calcium and phosphate homeostasis. Vitamin D<sub>3</sub> functions in the keratinocytes of skin, parathyroid glands, macrophages and T-cells of the immune system, ovarian cells and islet cells. 25-



hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase (CYP27B1) and 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> 24-hydroxylase (CYP24A1) are members of the cytochrome P450 superfamily, and key enzymes of vitamin D<sub>3</sub> metabolism for the activation and inactivation of vitamin D<sub>3</sub>, respectively (Sakaki *et al.*, 2005).

Since these CYPs are important enzymes in vitamin D<sub>3</sub> metabolism, understanding the possible effects of *Epilobium hirsutum* and *Viscum album*, as medicinal plants used in the treatment of several disorders, on CYP24A1 and CYP27B1 expressions may provide insight about the role of these plants in drug discovery and development.

### **1.1. *Epilobium hirsutum* L.**

*Epilobium hirsutum* L. is a tall, perennial and flowering plant between July-September with branched robust stems and numerous hairs (Figure 1.1). It is also called as hairy willow herb, great willow herb or great hairy willow herb and it is known as "Tüylü yakı otu" in Turkish (Baytop, 1999). *Epilobium hirsutum* is a member of the Onagraceae family. *Epilobium hirsutum* L. is a characteristic plant in Eurasia. It is found in moist waste, marshy ground of the Mediterranean region, Europe, Asia, and Africa. It forms large, long-lived colonies in England, Wales, and Ireland. Its height ranges from 30 cm to 2 meter tall. It has bright, pink-purple flowers with white centers and notched petals. Leaves are positioned oppositely and they attach directly on the stem (Stuckey, 1970).

*Epilobium hirsutum* L. is a semi-aquatic plant, so it prefers a wide range of moist soils, including wetlands, ditch and stream banks, low fields, pastures, and meadows to live. pH of 5.5 or higher is required by hairy willow-herb for the germination of seeds. Seeds and rhizomes are important for spreading of this plant. *Epilobium hirsutum* L. reproduces by wind dispersed. Also, vegetative reproduction occurs by thick rhizomes. Flower buds develop after 10 to 12 weeks of growth (Stuckey, 1970)



**Figure 1. 1** *Epilobium hirsutum* L.

The composition of *Epilobium hirsutum* L. is complex, because it has rich content including flavonoids (kaempferol, myricetin, quercetin etc.), free sterols ( $\beta$ -sitosterol and ester forms of  $\beta$ -sitosterol), tannins (Gallic, ellagic acid, protocatechuic and p-coumaric acids), polyphenols and ellagitannines (Ivancheva *et al.*, 1992; Barakat *et al.*, 1997; Gruenwald, 2000).

The total flavonoid content of *Epilobium hirsutum* L. is about 5.8% which provides intense phytotherapeutical effects (Roman *et al.*, 2010). Flavonoids have antioxidant properties of cleaning and buffering free radicals. Polyphenolic compounds are present

in plants which are medicinally used. They display many important biological effects such as antioxidant properties (Kähkönen *et al.*, 1999). Total phenolic content of *Epilobium hirsutum* L. is  $4.03 \pm 0.12$  mg of gallic acid equivalents (GAE)/100 g of dry weight (dw). *Epilobium hirsutum* L. has the phenolic acids and flavonoids indicated below:

Phenolic acids:

- Caffeic acid:  $23.1 \pm 0.03$  mg/100 g dw
- p-coumaric acid:  $38.3 \pm 0.09$  mg/100 g dw
- Ferulic acid:  $10.9 \pm 0.29$  mg/100 g dw

Flavonoids:

- Quercetin:  $214 \pm 0.03$  mg/100 g dw
- Myricetin:  $191 \pm 0.24$  mg/100 g dw (Wojdylo *et al.*, 2007)

It is used in folk medicine of Europe and Egypt for the treatment of prostate tumours, inflammation, and adenoma (Barakat *et al.*, 1997).

Internal usage of willow herb is thought to be beneficial for mucous membrane lesions in mouth, for micturition problems coming from prostatic hyperplasia (Stages I to II) and for gastrointestinal disorders. It is used for rectal bleeding by Native Americans; while it is used for menstrual disorders by Chinese people. External use of water extract of willow herb is for the improvement of the healing of wounds (Gruenwald, 2000). The body of *Epilobium hirsutum* L. is used as anti-inflammatory and edema preventer (Kiss *et al.*, 2011). The leaves and roots are used as anti-febrile drug and it is also important in the treatment of constipation and prostate (Barakat *et al.*, 1997). Also, *in vitro* studies showed that ethanolic extracts of *Epilobium hirsutum* L. displayed antimicrobial activity on gram-positive and gram-negative bacteria, fungi and yeasts (Battinelli *et al.*, 2001).

## **1.2. *Viscum album* L.**

*Viscum album* L. is a shrub which is widely used in folk medicine. It involves in the family of *Loranthaceae*. European Mistletoe is the common name of *Viscum album* L. (Barlow, 1987; Kuijt, 1990). It is also known as “ökseotu” in Turkish. It is the only species of this genus growing in Turkey. White berries with small and sticky shape are the characteristic for this plant. *Viscum album* L. also has long green, oppositely arranged leaves and small flowers which cannot be easily detected (Figure 1.2) (Tompkins, 2009). It has faint odor and bitter taste. *Viscum album* L. has a wide distribution all over the world especially in Europe, Northern Asia and Africa (*Committee for Veterinary Medicinal Products Viscum album Summary Report*, 2000). In Turkey, there are three subspecies of *Viscum album* L. namely, subsp. *album*, subsp. *abietis* (Wiesb.) Abromeit and subsp. *austriacum* (Wiesb.) Vollmann. These taxa have different hosts -various Dicotyledonous trees (subsp. *album*), fir trees (subsp. *abietis*) and pine trees (subsp. *austriacum*)- and therefore be generally identified if these are known (Davis, 1982).



**Figure 1. 2** *Viscum album* L.

*Viscum album* L. is a multi-component plant. The active chemical constituents in *Viscum album* L. are composed of;

- Glycoproteins:

High-molecular-weight glycoproteins composed of mistletoe lectins I, II, and III are the main constituents of *Viscum album* L. They are cytotoxic compounds with two chain structures; Chain A and Chain B. Chain A causes the inhibition of protein synthesis on the ribosomal stage. Chain B involves in the activation of macrophages and forces lymphocytes for releasing lymphokines. For mistletoe lectin I, Chain A together chain B prevent the release of histamine from leukocytes due to allergen induction. Both of these

chains also suppress release of serotonin from platelets caused by collagen induction (Franz, 1986).

The quantity and the degree of biological activity of this component depend on harvest time, manufacturing process and type of host tree (Büssing & Schietzel, 1999).

- Proteins:

Viscotoxin is a peptide which is composed of 46 amino acids and it is characteristic for *Viscum album* L. It is involved in cell membrane damage as well as enhancement of cytotoxic T-cells and granulocytes activity against bacteria and tumour cells.

- Polysaccharides:

Galacturonan and arabinogalactan are primary polysaccharides in *Viscum album* L. Esterified galacturonan is present in the leaves and stems of *Viscum album* L., while arabinogalactan primarily exists in the berries (Jordan & Wagner, 1986). In immune system, they function in the stimulation of T-helper cells, increase in NK-cell activity and interferon  $\gamma$  release.

- Alkaloids:

Alkaloids are nitrogenous compounds of *Viscum album* L. They are thought to be involved in cytotoxic property of mistletoe (Franz, 1986).

The other constituents involved in *Viscum album* L. are flavonoids, sulphurous components, caffeic acids, phenylpropane derivatives, mucilages, phytosterols, stigmasterol, cyclitols, amines including histamine and acetylcholine, triterpenoids and phytosterols (*Committee for Veterinary Medicinal Products Viscum album Summary Report*, 2000; Tompkins, 2009).

*Viscum album* L. is used extensively in alternative medicine to prevent or treat several diseases and disorders. In Turkey, the plant is used for cardiac disorders and

hypertension in the Middle, East and Southeast Anatolia and in diabetes by the inhabitants of Beypazarı, Ankara, Turkey (Baytop, 1999; Gencler-Ozkan & Koyuncu, 2005; Yucecan *et al.*, 1988; Simsek *et al.*, 2004; Gupta *et al.*, 2012). In addition, the preparations of *Viscum album* L. have been used clinically in adjuvant cancer therapy in Europe and therefore, various studies have been conducted on the plant since 1926 (Yesilada *et al.*, 1998).

The pharmacological studies which have been documented up to now have focused on immune-stimulant, cardiotoxic and cytotoxic abilities of *Viscum album* L. (Gupta *et al.*, 2012). The active role of *Viscum album* L. in nervous disorders, joint and bone disorders such as arthritis, cardiovascular diseases including atherosclerosis and hypertension, was demonstrated with several studies (Wichtl & Bisset, 1994; Bartram, 1998; Murray, 1995; Newall *et al.*, 1996).

The studies of Kienle (2010) and Mitchell (2003) showed that *Viscum album* L. has role in the enhancement of macrophage ability in phagocytosis. The active components of *Viscum album* L., lectins and viscotoxins, exhibit growth inhibition and cytotoxic effects. *Viscum album* L. involves in stimulation of thymus glands and improves the activation of T-cells, granulocytes, monocytes, natural killer cells and dendritic cells for strengthening the immune system. It also has DNA stabilizing properties (Tompkins, 2009).


Moreover, in cardiovascular system, *Viscum album* L. directly affects the cholinergic pathways which are important in decreasing the blood pressure (Wagner & Jordan, 1986). *Viscum album* L. has reputation due to showing anti-mycobacterial (Deliorman *et al.*, 2001a, b), anticancer (Burger *et al.*, 2001), anti-inflammatory (Hegde *et al.*, 2011), hypotensive (Ofem *et al.*, 2007), antioxidant and hypoglycemic (Orhan *et al.*, 2005) properties.

## **1.3. Vitamin D<sub>3</sub> and its metabolism**

### **1.3.1. Introduction**


Vitamin is defined as an organic compound which is not synthesized in the body even it is essential for the organism and it must be acquired from the diet. According to this definition, vitamin D is not a vitamin at all. More than this classical definition, vitamin D is described as a prohormone, so it must be metabolized to its biologically active form so that it can function as a steroid hormone (Omdahl *et al.*, 2002; Sutton & MacDonald, 2003). Vitamin D is the general name for a group of chemically related compounds. Vitamin D<sub>2</sub> and vitamin D<sub>3</sub> are the most important members of this group (Figure 1.3). Vitamin D<sub>2</sub> also called as ergocalciferol is derived from ergosterol, which is a plant steroid. Vitamin D<sub>3</sub> is also known as cholecalciferol and it is synthesized from 7-dehydrocholesterol through UV irradiation (Figure 1.4). Besides the biosynthesis, both vitamin D<sub>2</sub> and vitamin D<sub>3</sub> can be taken from the dietary sources.





**Figure 1. 3** Nutritional forms of vitamin D.

Vitamin D<sub>3</sub> contains three intact rings with three double bonds in its structure. It is formed by irradiation of 7-dehydrocholesterol (Figure 1.4). Normally, Vitamin D<sub>3</sub> is unstable in light and it undergoes oxidation reaction if it is exposed to air at 24 °C for 72 hours. Best storage temperature for vitamin D<sub>3</sub> is 0 °C (Norman & Henry, 2007).




**Figure 1. 4** Chemistry and irradiation pathway for production of vitamin D<sub>3</sub>.

### 1.3.2. Vitamin D<sub>3</sub> metabolism

When skin is exposed to ultraviolet light (270-300 nm), 7-dehydrocholesterol in the skin is converted to vitamin D, in the form of vitamin D<sub>3</sub>. Dietary intake is the other source for the uptake of vitamin D<sub>3</sub>. Vitamin D<sub>3</sub> circulation in the bloodstream does not take place for very long time. It can be stored in the adipose tissues or further metabolized in the liver. Vitamin D<sub>3</sub> can be stored for months or years in humans; however finally it undergoes metabolic reactions (Figure 1.5). The first step for the activation of vitamin D<sub>3</sub> after UV irradiation is 25-hydroxylation reaction which takes place mainly in the

liver. A hydroxyl group is added to 25-carbon to generate 25(OH)-D<sub>3</sub>. Vitamin D<sub>3</sub> 25-hydroxylase enzyme catalyzes the formation of 25(OH)-D<sub>3</sub>. After 25-hydroxylation in liver, 25(OH)D<sub>3</sub> again comes to circulatory system. In the circulatory system, vitamin D binding protein (DBP) transports 25(OH)D<sub>3</sub> to the kidney for the addition of another hydroxyl group at the C-1 position into the A ring (Norman & Henry, 2007). This reaction is catalyzed by 1 $\alpha$ -hydroxylase. As a result of 1 $\alpha$ -hydroxylation, 1,25(OH)<sub>2</sub>D<sub>3</sub> is formed as an active form of vitamin D<sub>3</sub>. Although there are other tissues for this reaction such as liver, 1 $\alpha$ -hydroxylation mainly takes place in kidney.



**Figure 1. 5** Pathways of vitamin D activation and inactivation (St-Arnaud, 2011).

The catabolism of vitamin D<sub>3</sub> compounds which are 25(OH)D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub> is carried out by 24-hydroxylation. This reaction is catalyzed by 24-hydroxylase and it is also known as CYP24A1. C-24 oxidation pathway primarily takes place in kidney even there are other sites in the body for this reaction such as liver.

### **1.3.2.1. 25-hydroxylation**

25-hydroxylation is the first reaction for the activation of vitamin D<sub>3</sub>. This reaction is catalyzed by 25-hydroxylase enzyme which is primarily found in liver. Besides liver, in intestinal, skin and renal extracts, 25-hydroxylase activity was found (Tucker *et al.*, 1973). The product of this reaction is 25(OH)D<sub>3</sub> which is the main circulating form of vitamin D<sub>3</sub> due to the stability coming from the binding to vitamin D-binding protein (DBP) (Cooke & Haddad, 1989; Cooke *et al.*, 1991). Serum level of 25(OH)D<sub>3</sub> is used as an indicator for vitamin D status, since its level is directly affected by increased uptake of vitamin D. The following metabolism of 25(OH)D<sub>3</sub> depends on the calcium level in the animals. According to requirements or abundance of calcium, it undergoes further activation or inactivation, respectively. Requirement of calcium causes 1 $\alpha$ -hydroxylation of 25(OH)D<sub>3</sub>; however excess amount of calcium leads to 24-hydroxylation of 25(OH)D<sub>3</sub>.

The subcellular locations of 25-hydroxylation are mitochondria and microsomes (Norman & Henry, 2007). In humans, there are two types of 25-hydroxylase enzyme; CYP2R1 and CYP27A1. CYP2R1 is a microsomal 25-hydroxylase with high specificity and low capacity. Unlike CYP2R1, CYP27A1 is a mitochondrial 25-hydroxylase with low affinity, but high capacity.

### 1.3.2.2. 1 $\alpha$ -hydroxylation

After 25-hydroxylation, the following step for the activation of vitamin D<sub>3</sub> is 1 $\alpha$ -hydroxylation which converts 25(OH)D<sub>3</sub> to 1,25(OH)<sub>2</sub>D<sub>3</sub> –the active form of vitamin D<sub>3</sub>. A second hydroxyl group is introduced into A ring at 1 $\alpha$  position by 1 $\alpha$ -hydroxylase which is also known as CYP27B1. Kidney is the major organ for this reaction; however recent studies showed that CYP27B1 expression was detected in non-renal tissues such as skin, intestine, liver, bone, brain, macrophages and testis (Zehnder *et al.*, 2001). CYP27B1 protein and mRNA expression are under tight regulation by several factors. Parathyroid hormone (PTH) potentially stimulates the transcription and activity of CYP27B1 in the kidney, and this stimulation is mediated through cAMP/phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) signal transduction pathway at the molecular level (Henry & Luntao, 1989). Calcitonin also involves in upregulation of CYP27B1 (Shinki *et al.*, 1999). Unlike PTH and calcitonin, 1,25(OH)<sub>2</sub>D<sub>3</sub> down-regulates the PTH-stimulated CYP27B1 gene activation (Brenza & DeLuca, 2000).

### 1.3.2.3. 24-hydroxylation

Further metabolism of 1,25-(OH)<sub>2</sub>D<sub>3</sub> is the 24-hydroxylation. This reaction is catalyzed by 24-hydroxylase enzyme and it is also known as CYP24A1. CYP24A1 is found in mitochondrial inner membrane and mainly functions in kidney. The initial product of this reaction is short-lived 1,24,25(OH)<sub>3</sub>D<sub>3</sub>. 25(OH)D<sub>3</sub> is also substrate of CYP24A1 and this reaction causes the formation of 24,25(OH)<sub>2</sub>D<sub>3</sub> which is circulating in bloodstream.

1,25(OH)<sub>2</sub>D<sub>3</sub> stimulates the expression of *CYP24A1* gene in target tissues of vitamin D<sub>3</sub>, especially in intestine and kidney. Unlike 1,25(OH)<sub>2</sub>D<sub>3</sub>, PTH represses the CYP24A1 activity in kidney.(Reinhardt & Horst, 1990; Shinki *et al.*, 1992; Zierold *et al.*, 2000) In kidney, suppressed CYP24A1 by PTH may cause an increase in 1,25(OH)<sub>2</sub>D<sub>3</sub> and circulating calcium level. (Bai *et al.*, 2003; Inoue *et al.*, 2005; Larsson *et al.*, 2004; Perwad *et al.*, 2007).

### 1.3.3. Factors affecting the vitamin D<sub>3</sub> metabolism

PTH is one of the factors that affect the vitamin D<sub>3</sub> metabolism. In case of low circulating calcium level, PTH works as a potent stimulator for the production of 1,25(OH)<sub>2</sub>D<sub>3</sub>. PTH leads to upregulation of CYP27B1 mRNA expression (St-Arnaud *et al.*, 1997) as well as enzymatic activity (Garabedian *et al.*, 1972) in the kidney. This regulation was shown with the studies on parathyroidectomised animals. CYP27B1 enzyme activity was stimulated in parathyroidectomised animals when they were treated with PTH (Lobaugh *et al.*, 1993; Weisinger *et al.*, 1989). The induction of 1,25(OH)<sub>2</sub>D<sub>3</sub> by PTH occurs through receptor-mediated cAMP/PIP<sub>2</sub> signal transduction mechanism (Henry *et al.*, 1992). Unlike the effect of PTH on CYP27B1 activity, PTH represses the CYP24A1 activity in the kidney (Shinki *et al.*, 1992). This negative effect is not present in other tissues such as intestine due to the lack of PTH receptors (Abou-Samra *et al.*, 1994).

The other factor affecting the vitamin D<sub>3</sub> metabolism is calcium. The interaction of calcium with calcium-sensing receptors (CaR) present in the parathyroid gland indirectly affects the 1,25(OH)<sub>2</sub>D<sub>3</sub> production in the kidney. Low level of calcium stimulates the parathyroid cells to produce PTH resulting in increased production of 1,25(OH)<sub>2</sub>D<sub>3</sub>. There is also direct regulation of 1,25(OH)<sub>2</sub>D<sub>3</sub> by calcium in the kidney. In PTH-repleted rats, it was shown that increase in calcium level causes decrease in circulating 1,25(OH)<sub>2</sub>D<sub>3</sub> level (Matsumoto *et al.*, 1987; Weisinger *et al.*, 1989). It was suggested that this regulation is mediated through CaR.

Calcitonin also involves in regulation of vitamin D<sub>3</sub> metabolism. Unlike PTH-mediated stimulation under hypocalcemia, calcitonin particularly involves in the stimulation of CYP27B1 mRNA expression in the kidney when circulating calcium level is normal (Shinki *et al.*, 1999). In the promoter region of CYP27B1 gene, there is a positive regulatory site for calcitonin.

1,25(OH)<sub>2</sub>D<sub>3</sub> leads to upregulation of CYP24A1 activity. When 1,25(OH)<sub>2</sub>D<sub>3</sub> binds to VDR, they directly induce the mRNA expression of CYP24A1 due to the interaction with VDREs present on the promoter region of CYP24A1 gene (Hahn *et al.*, 1994; Kerry *et al.*, 1996). On the other hand, 1,25(OH)<sub>2</sub>D<sub>3</sub> suppresses the CYP27B1 activity in the kidney. Since no VDREs have been found in the proximal promoter region of CYP27B1 gene, probably the mechanism of suppression by 1,25(OH)<sub>2</sub>D<sub>3</sub> is indirect and requires other factors such as PTH or calcium (Brenza & DeLuca, 2000).

#### **1.3.4. Biological actions of 1,25(OH)<sub>2</sub>D<sub>3</sub>**

There is coordination between kidney, bone, intestine and parathyroid gland for the maintenance of calcium homeostasis. This coordinated mechanism provides enough calcium to achieve muscle and nerve function as well as maintenance of bone mineralization. Although the exact role of 1,25(OH)<sub>2</sub>D<sub>3</sub> is still under question, it has recently found that there is an association between 1,25(OH)<sub>2</sub>D<sub>3</sub> and immune system, pancreas, ovarian cells and some neuronal tissues.

The main role of 1,25(OH)<sub>2</sub>D<sub>3</sub> in small intestine is the stimulation of calcium absorption. This stimulation is carried out through VDR-mediated transcription regulation of the genes specific to calcium absorption. In particularly, calbindin-D9k is a cytosolic calcium-binding protein important in calcium translocation across the enterocyte. 1,25(OH)<sub>2</sub>D<sub>3</sub> leads to up-regulation of calbindin-D9k expression together with VDRE which is found to be proximal region of gene promoter (Darwish & DeLuca, 1996). Besides this mode of action of 1,25(OH)<sub>2</sub>D<sub>3</sub>, the direct role of 1,25(OH)<sub>2</sub>D<sub>3</sub> for the regulation of calbindin-D9k was shown in VDR knockout mice. Both protein and mRNA expression were decreased when the intestinal VDR was knocked-out (Li *et al.*, 1998).

In vitamin D-deficient and VDR-knocked out animals, normal bone mineralization was detected when they were fed high level calcium (Weinstein *et al.*, 1984). It suggests that  $1,25(\text{OH})_2\text{D}_3$  does not have a key role in bone mineralization. The main point in defective mineralization may be the defective intestinal absorption which affects the availability of phosphorus and calcium. However, *in vitro* studies showed that  $1,25(\text{OH})_2\text{D}_3$  is involved in regulation of mineralization, transcription and differentiation of osteoblast gene (Matsumoto *et al.*, 1991; Rickard *et al.*, 1995). Osteocalcin and osteopontin are the bone matrix proteins having VDRE in their promoter sites.  $1,25(\text{OH})_2\text{D}_3$  induces the transcription of the genes which encodes for these proteins.  $1,25(\text{OH})_2\text{D}_3$  also function in stimulation of osteoclast development indirectly by generating osteoblast-derived factor which then affects the osteoclastogenesis (Abe *et al.*, 1981; Suda *et al.*, 1995; Tanaka *et al.*, 1982).

PTH is involved in stimulation of  $1,25(\text{OH})_2\text{D}_3$  production in kidney as a result of hypocalcemia, so  $1,25(\text{OH})_2\text{D}_3$  provides negative feedback regulation by suppressing PTH secretion and synthesis from parathyroid glands (Cantley *et al.*, 1985; Chan *et al.*, 1986) as well as by growth control of parathyroid cells (Szabo *et al.*, 1989). There is VDRE in the promoter site of PTH gene, so it is under direct regulation by  $1,25(\text{OH})_2\text{D}_3$ -bound VDR-RXR heterodimer (Liu *et al.*, 1996).

$1,25(\text{OH})_2\text{D}_3$  shows negative feedback regulation for its own synthesis by suppressing CYP27B1 and stimulating CYP24A1 in kidney. Also,  $1,25(\text{OH})_2\text{D}_3$  stimulates the expression of calbindin-28k which functions in calcium transport in kidney (Bar *et al.*, 1990; Varghese *et al.*, 1988).  $1,25(\text{OH})_2\text{D}_3$  has also been associated with facilitation of calcium reabsorption and calcium transport regulated by PTH in kidney (Friedman & Gesek, 1993; Yamamoto *et al.*, 1984).



## **1.4. Cytochrome P450s**


### **1.4.1. Introduction**

Cytochrome P450 (CYP) is the general name of a large family of different enzymes metabolizing most of the drugs and chemicals. The term P450 refers to a pigment that absorbs light at 450 nm when reduced form is exposed to carbon monoxide (Omura and Sato, 1964). Besides xenobiotic metabolism, many CYP enzymes have important roles in different physiological processes. Cholesterol and steroid biosynthesis, metabolism of fatty acids and calcium homeostasis and its maintenance are the most important physiological processes in which CYP enzymes involve (Mckinnon *et al.*, 2008).

### **1.4.2. Nomenclature**

The nomenclature of a cytochrome P450 gene includes (Figure 1.6):

- The abbreviation CYP for cytochrome P450;
- Following number indicating for the CYP family;
- Capital letter for the subfamily; and
- Final numeral representing for the individual gene (Nebert *et al.*, 1987).



**Figure 1. 6** Nomenclature of cytochromes P450.

For describing a CYP gene, italic letters and numerals are used. For the CYP enzymes, same nomenclature in non-italic form is used.

It is thought that divergence of CYP families from each other took place about 1.2 billion years ago. Therefore, at least 40% amino acid sequence homology is required to be involved in the same family. Divergence of the subfamilies is estimated to occur 400 million years ago. For being in the same subfamily, greater than 55% identity is prerequisite (Coleman, 2005).


### **1.4.3. Mechanism**

CYPs can be classified into four groups according to delivery of electrons from NAD(P)H to the catalytic sites;

- CYPs with iron sulfur redoxin and FAD-containing reductase;
- CYPs with FAD/FMN-containing P450 reductase;
- Self-sufficient CYPs with no requirement for electron donor; and

- CYPs with direct electron transfer from NAD(P)H (Werck-Reichhart & Feyereisen, 2000).

Despite the electron delivery differences, all CYP enzymes share a common catalytic mechanism for the oxygenation of a substrate (Figure 1.7).



**Figure 1. 7** Generalized cytochrome P450 catalytic cycle for the oxidation of substrates (Guengerich, 2001).

Binding of substrate (RH) to the ferric ( $\text{Fe}^{3+}$ ) form of CYP enzyme initiates the cycle. After the initiation of the cycle, electron transfer from NAD(P)H is carried out and this transfer reduces the iron atom and changes it into ferrous state ( $\text{Fe}^{2+}$ ). Then,  $\text{O}_2$  binds to ferrous form of CYP enzyme producing an unstable structure, and it leads to generation of superoxide anion and ferric iron. After this step, NADPH-P450 reductase or NADH-cytochrome  $\text{b}_5$  reductase inserts a further electron and a proton ( $\text{H}^+$ ) into the cycle.  $\text{H}_2\text{O}$  is then released and high-valent  $\text{FeO}^{3+}$  complex formed after the breakage of Fe O-O bond. Direct interaction of  $\text{FeO}^{3+}$  with the substrate leaves an electron or hydrogen atom; therefore the product dissociates from the CYP enzyme and the cycle is completed (Zeldin, 2008).

#### **1.4.4. Tissue distribution and function**

Generally, CYP enzymes are found most abundantly in liver, where most of the drugs and endogenous substances are metabolized. Besides liver, several isoforms of CYP enzymes are found in extrahepatic tissues. CYP expression also takes place in kidney, heart, lung, brain, olfactory mucosa and gastrointestinal tract (Zeldin, 2008; Adali & Arinc, 1990; Arinc *et al.*, 1995; Adali *et al.*, 1996; Arinc *et al.*, 2000).

CYP enzymes show differences in terms of function (Table 1.1). They can participate in xenobiotic metabolism as well as metabolism of endogeneous compounds.

**Table 1. 1** Human cytochrome P450 genes (Nelson, 2009).

<b>Human P450 families</b>	<b>Functional members</b>	<b>Main functions</b>
CYP1 (3 subfamilies)	1A1, 1A2, 1B1	Drug/xenobiotic metabolism
CYP2 (13 subfamilies)	2A6, 2A7, 2A13, 2B6, 2C8, 2C9, 2C18,2C19, 2D6, 2E1, 2F1, 2J2, 2R1, 2S1, 2U1, 2W1	Drug/xenobiotic metabolism and steroid metabolism
CYP3 (1 subfamily)	3A4, 3A5, 3A7, 3A43	Drug/xenobiotic metabolism
CYP4 (6 subfamilies)	4A11, 4A22, 4B1, 4F2, 4F3, 4F8, 4F11, 4F12, 4F22, 4V2, 4X1, 4Z1	Arachadonic acid and fatty acid metabolism
CYP5 (1 subfamily)	5A1	Thromboxane A <sub>2</sub> synthesis
CYP7 (2 subfamilies)	7A1, 7B1	Rate-limiting step of bile acid biosynthesis (cholesterol elimination)
CYP8 (2 subfamilies)	8A1, 8B1	Prostacyclin and bile acid biosynthesis
CYP11 (2 subfamilies)	11A1, 11B1, 11B2	Key steps in steroid biosynthesis
CYP17 (1 subfamily)	17A1	Testosterone and oestrogen biosynthesis
CYP19 (1 subfamily)	19A1	Oestrogen biosynthesis (aromatase)
CYP20 (1 subfamily)	20A1	Unknown
CYP21 (1 subfamily)	21A2	Steroid biosynthesis
CYP24 (1 subfamily)	24A1	Vitamin D metabolism/inactivation
CYP26 (3 subfamilies)	26A1, 26B1, 26C1	Retinoic acid metabolism/inactivation
CYP27 (3 subfamilies)	27A1, 27B1, 27C1	Bile acid biosynthesis, vitamin D activation
CYP39 (1 subfamily)	39A1	Cholesterol metabolism
CYP46 (1 subfamily)	46A1	Cholesterol metabolism
CYP51 (1 subfamily)	51A1	Cholesterol biosynthesis

Besides these functional human P450 genes, there are 58 pseudogenes being determined (Nelson, 2009).

There are two types of cytochrome P450 enzymes which are type I and type II forms. Type I form of CYP enzymes are the mitochondrial enzymes while type II forms are found in the endoplasmic reticulum. Most of the vitamin D<sub>3</sub> metabolizing enzymes are involved in type I forms CYP enzymes. They function as oxidases and use electrons coming from molecular oxygen and NADPH (Black & Coon, 1987; Nebert, 1987).


Among these CYP enzymes, CYP24A1 and CYP27B1 enzymes are two most important enzymes involved in Vitamin D<sub>3</sub> metabolism.

#### **1.4.5. Cytochrome P45024A1 (CYP24A1)**

CYP24A1 (EC.1.14.13.126) is the member of cytochrome P450 enzymes which is also known as 25-hydroxyvitamin D<sub>3</sub>-24-hydroxylase. It is a mitochondrial inner membrane enzyme with 65 kDa molecular weight and composed of 514 amino acids. The crystal structure of CYP24A1 is given in Figure 1.8. It catalyzes the conversion of 25-hydroxyvitamin D<sub>3</sub> (25-OH-D<sub>3</sub>) and 1,25-dihydroxyvitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>) into the corresponding 24-hydroxylated products. Therefore, it has important role in the degradation of vitamin D<sub>3</sub> molecules.

For the degradation process, CYP24A1 catalyzes the 24-hydroxylation reaction of both 25-OH-D<sub>3</sub> and 1,25-(OH)<sub>2</sub>D<sub>3</sub>. *K<sub>m</sub>* value for 25-OH-D<sub>3</sub> is ten times higher than *K<sub>m</sub>* value for 1,25-(OH)<sub>2</sub>D<sub>3</sub>, meaning that 1,25-(OH)<sub>2</sub>D<sub>3</sub> is more preferable substrate of CYP24A1. CYP24A1 is mainly responsible for the 24-hydroxylation of 1,25-(OH)<sub>2</sub>D<sub>3</sub>, which results in the production of calcitroic acid, a biliary catabolite (Makin *et al.*, 1989; Reddy & Tserng, 1989). Also, CYP24A1 catalyzes the 23-hydroxylation reaction with the end-product, 1,25-(OH)<sub>2</sub>D<sub>3</sub>-26,23-lactone (Sakaki *et al.*, 2000; Yamada *et al.*, 1984).

CYP24A1 gene expression is strongly stimulated by  $1,25\text{-(OH)}_2\text{D}_3$  while PTH involves in the suppression of 24-hydroxylase activity in the kidney.



**Figure 1. 8** Crystal Structure of rat CYP24A1 with  $1,25\text{-(OH)}_2\text{D}_3$  (Annalora *et al.*, 2010).

*CYP24A1* gene is not only expressed in kidney, but also expressed in many vitamin D target tissues which contain vitamin D receptor (VDR) such as bone, intestine and liver (Jones *et al.*, 1998). According to promoter analysis of *CYP24A1* gene in human and rats, two vitamin D responsive elements (VDREs) are required for the induction by 1,25-(OH)<sub>2</sub>D<sub>3</sub> via vitamin D receptor (VDR). One of them is present around -150 bp (proximal) and the other is localized to -250 bp (distal) (Hahn *et al.*, 1994; Kerry *et al.*, 1996; Ohyama *et al.*, 1994, 1996; Zierold *et al.*, 1994, 1995).

Besides the catabolism of vitamin D<sub>3</sub> compounds, CYP24A1 also functions in removal of several vitamin D analogs such as the ones used in treatment of chronic kidney diseases in the world: 22-oxa-1,25-(OH)<sub>2</sub>D<sub>2</sub> (maxacalcitol), 1 $\alpha$ -OH-D<sub>2</sub> (doxercalciferol) and 19-nor-1,25-(OH)<sub>2</sub>D<sub>2</sub> (paricalcitol) (Masuda *et al.*, 1994; Masuda *et al.*, 2006; Shankar *et al.*, 2001). All these analogs undergo C-23 or/and C-24 metabolism by CYP24A1.


Since the increase in CYP24A1 expression may cause the vitamin D deficiency, it was suggested that CYP24A1 may be used as a potential therapeutic target and the inhibitors of CYP24A1 enzyme can be used in the treatment of enhanced vitamin D catabolism-related diseases. These CYP24A1 inhibitors include;

- Genistein, which is a natural product found in soya products (Cross *et al.*, 2004; Farhan & Cross, 2002)
- General azole-based inhibitors, which functions by binding to the heme region at the catalytic core of CYP24A1 enzyme (Ly *et al.*, 1999; Muindi *et al.*, 2010)
- A family of imidazole derivatives, which involves in increasing the selectivity of CYP24A1 and vitamin D signaling (Schuster *et al.*, 2001)
- Highly-CYP24A1 specific inhibitors, which are potent CYP24A1 inhibitor and highly-selective (Posner *et al.*, 2010)



#### 1.4.6. Cytochrome P45027B1 (CYP27B1)

CYP27B1 (EC.1.14.13.13) is the member of cytochrome P450 enzymes and it involves in the XXVIIB subfamily of the cytochrome P450 family. It is also known  $1\alpha$ -hydroxylase. CYP27B1 is a mitochondrial inner membrane enzyme with 55 kDa molecular weight and composed of 508 amino acids. The three dimensional structure model is given in Figure 1.9. It catalyzes  $1\alpha$ -hydroxylation of 25-OH-D<sub>3</sub> to form 1,25-(OH)<sub>2</sub>D<sub>3</sub> which is the active form of vitamin D<sub>3</sub>.



**Figure 1. 9** Three-dimensional structure model of CYP27B1. The structure was constructed by homology modeling technique (Sakaki *et al.*, 2005).

CYP27B1 gene expression is tightly regulated by 1,25-(OH)<sub>2</sub>D<sub>3</sub>, PTH and calcitonin (Sutton & MacDonald, 2003). Calcitonin and PTH have role in the upregulation of CYP27B1 gene expression (Shinki *et al.*, 1999). On the other hand, 1,25-(OH)<sub>2</sub>D<sub>3</sub> which is the end-product of the reaction catalyzed by CYP27B1 is the down-regulator of gene expression of CYP27B1 at the transcriptional level (Murayama *et al.*, 1998).

Vitamin D-dependent ricket type I which is also known as pseudo-vitamin D deficiency rickets is a kind of autosomal recessive inherited disorder. Secondary hyperparathyroidism, low serum level of calcium and low levels of circulating 1,25-(OH)<sub>2</sub>D<sub>3</sub> are the characteristics of this disorder. Genome analysis of the patients showed some missense mutations, insertions and deletions in *CYP27B1* gene (Fu *et al.*, 1997; Kitanaka *et al.*, 2002; Wang *et al.*, 1998; Yoshida *et al.*, 1998). Besides the genome analysis, *Cyp27b1* knockout mouse studies revealed compatible results with vitamin D-dependent ricket type I and 1,25-(OH)<sub>2</sub>D<sub>3</sub> was not detected in circulation (Dardenne *et al.*, 2001; Panda *et al.*, 2001). These studies showed that CYP27B1 is the only enzyme for the 1 $\alpha$ -hydroxylation of 25-OH-D<sub>3</sub> to synthesize 1,25-(OH)<sub>2</sub>D<sub>3</sub>.

## 1.5. Aim of the study

Plants have always played important roles in human life and they are also used in medicine throughout the history. They have been traditionally used for both treatment and prevention of diseases. Many of the modern medicines are produced indirectly from medicinal plants. *Epilobium hirsutum* L. (hairy willow herb) and *Viscum album* L. (European mistletoe) are the two medicinally important plants which are used in the treatment of several diseases and disorders. *Epilobium hirsutum* L. is used in treatment of inflammation, menstrual disorders, prevention of rectal bleeding and treatment of constipate and prostate. *Viscum album* L. has also been reputed against cardiovascular diseases (hypertension and atherosclerosis), various bone and joint disorders including peri-arthritis and arthritis. These plants contain many biologically active compounds such

acid phenolic acids and flavonoids, and these compounds provide some important biological activities including anti-inflammatory and antioxidant actions. Besides these properties, these plants may have effects on enzymes involved in physiological processes such as vitamin D<sub>3</sub> metabolizing enzymes, CYP24A1 and CYP27B1 which are responsible for the inactivation and activation of vitamin D<sub>3</sub>, respectively. Nevertheless, there is no data available in the literature for the possible effects of *Epilobium hirsutum* L. and *Viscum album* L. on vitamin D<sub>3</sub> metabolizing CYP24A1 and CYP27B1 enzymes. Therefore, in the present study, it was aimed to show the possible *in vivo* effects of the medicinal plants *Epilobium hirsutum* L. and *Viscum album* L. on vitamin D<sub>3</sub> metabolizing CYP24A1 and CYP27B1 enzymes.

For this purpose, these medicinal plants were collected from unpolluted stream beds and their water extracts were obtained. Then, the extracts were injected to the albino wistar rats (*Rattus norvegicus*) intraperitoneally for nine consecutive days. After decapitation of the animals, their livers were removed and S1.5 fractions were prepared by homogenization and centrifugation. The rat liver S1.5 fractions were used for determination of CYP24A1 and CYP27B1 protein expressions by Western blot technique. Quantitative real-time PCR was carried out by using cDNA synthesized from total RNA of rat livers to determine the mRNA expressions.

So far, there has not been such a study about the effects of these plants on vitamin D<sub>3</sub> metabolizing enzymes. This study is the first one concerning the effects of medicinal plants *Epilobium hirsutum* L. and *Viscum album* L. on rat liver CYP24A1 and CYP27B1 protein and mRNA expression.

## CHAPTER 2

### MATERIALS & METHODS

#### 2.1. Materials

Boric acid (A949265), chloroform (1.02431.2500), copper (II) sulfate pentahydrate ( $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; A894987 605), folin-phenol reagent (1.09001.0500), magnesium chloride ( $\text{MgCl}_2$ ; Art.5833), potassium chloride (KCl; 4935), sodium carbonate ( $\text{Na}_2\text{CO}_3$ ; 1.06392), sodium chloride (NaCl; 1.06400), sodium hydroxide (NaOH; 06462), zinc chloride ( $\text{ZnCl}_2$ ; 108815) were purchased from E. Merck, Darmstadt, Germany.

Acrylamide (A-8887), ammonium per sulfate (APS; A-3678), bovine serum albumin (BSA; A788), bromophenol blue (B5525), diethanolamine (D-2286), diethylpyrocarbonate (DEPC; D5758), ficoll (F2637), glycerol (G5516), glycine (G-7126),  $\beta$ -mercaptoethanol (M6250), methanol (34885), N'-N'-bis-methylene-acrylamide (M7256), N-N-dimethylformamide (D-8654), phenazine methosulfate (P9625), secondary antibody AP mouse (A3562), secondary antibody AP rabbit (A3687), sodium dodecyl sulfate (SDS; L4390), sodium-potassium (Na-K) tartarate (S-2377), tween 20 (P1379), xylene cyanol (X4126) were the products of Sigma, Aldrich, Germany.

5-bromo 4-chloro 3-indoyle phosphate (BCIP; R0821), dithiothreitol (DDT; R0861), gene ruler<sup>TM</sup> 50 bp DNA ladder (SM0371), light cycler-fast start DNA Master<sup>Plus</sup> SYBR green I (K0252), Maloney murine leukemia virus reverse transcriptase (M-MuLu-RT;

K1622), pre-stained protein ladder (SM0671) were purchased from MBI Fermentas, USA.

Primary antibody 24A1 (sc-66851) and primary antibody 27B1 (sc-67260) were purchased from Santa Cruz Biotechnology, Inc. USA.

Non-fat dry milk (170-6404) and tetra methyl ethylene diamine (TEMED; 161-0801) were the products of Bio-Rad Laboratories, Richmond, California, USA.

Ethylene diamine tetra acetic acid (EDTA; A5097) and nitrotetrazolium blue chloride (NBT; A1243) were acquired from Applichem GmbH, Germany.

Ethanol (32221) was obtained from Riedel de-Haen Chemical Company, Germany. Isopropanol (AS040-L50) was the product of Atabay, İstanbul, Turkey. TRIzol<sup>®</sup> (12183-555) was purchased from Invitrogen.

## **2.2. Methods**

### **2.2.1. Collection of the plants and extraction procedure**

Flowering aerial parts of hairy willow-herb were collected from Gölyaka, Düzce, Turkey, at an altitude of 563 m., in June 2009. The plant was identified as *Epilobium hirsutum* L. (Davis, 1972) and a voucher specimen (No:AEF 25812) was deposited in Herbarium of Faculty of Pharmacy, Ankara University (AEF). European mistletoe samples growing on pine trees (*Pinus sylvestris* L.) were collected from Melikgazi village of Pınarbaşı district (Kayseri, Turkey) in August 2008 at an altitude of 1800 m. and identified as *Viscum album* L. subsp. *austriacum* (Wiesb.) Vollmann according to Flora of Turkey and the East Aegean Islands (Davis, 1982). Voucher specimen (No:AEF 25945) was deposited in AEF for future reference. From among the three subspecies

growing in Turkey, *Viscum album* L. subsp. *austriacum* (Wiesb.) Vollmann was chosen for this study, because in Turkish Folk Medicine it is generally thought to be more effective than the rest (Personal field work observation).

50 g of crushed and powdered plant tissue for each taxon was subjected to active maceration in sterile ddH<sub>2</sub>O by using Heidolph mechanic shaker at 300 rpm/minute at room temperature for 8 hours. Obtained extract was filtered from whatman filter paper and dried in the freeze drying machine (Christ Gamma 2-16 LSC) and weighed. Finally, after yield calculations (15% for *Epilobium hirsutum* L; 19% for *Viscum album* L.: weight/weight), the plant extracts were stored at -20°C without any oxygen interaction until using for the experiments.

This part of the study was carried out with the collaboration of Ankara University, Faculty of Pharmacy.

### **2.2.2. Animal Studies**

Male Wistar Albino rats (*Rattus norvegicus*) which were 12 weeks old and weighing 200-250 g were purchased from Experimental Research Department of Pamukkale University, Denizli. They were housed University Animal House in standard conditions and fed with standard diet with water and libitum. All experimental procedures in animals such as administration of substances by i.p., collection of blood and tissues etc. were performed according to national standards under appropriate regimes with Veterinary services and in accordance with the Declaration of Helsinki (ethical committee reports are at Appendix A).

For the experiment, rats were randomly assorted into the following three groups:

**C:** Control group with water injection

**EHT:** *Epilobium hirsutum* L.-treated group

**VAT:** *Viscum album* L.- treated group

37.5 mg water extract of *Epilobium hirsutum* L. /kg body weight/day was intraperitoneally (i.p) injected to 25 rats for 9 consecutive days. For *Viscum album*-treated group, 10 mg water extract of *Viscum album* L./kg body weight/day was intraperitoneally (i.p) injected to 15 animals for 9 days. 11 rats were used as a control group and no treatment was done. At the end of the experimental period and following 16 h of fasting, the animals were sacrificed. The livers were isolated and stored at -80 °C until used for preparation of S1.5 fractions. This part of the study was carried out with the collaboration of Pamukkale University, Biology Department.

### **2.2.3. Preparation of Rat Liver S1.5 Fraction**

Rat liver S1.5 fraction was prepared by the method of Schenkman and Cinti (1978) as optimized by Sen and Kirikbakan (2004). After blotting the tissues by the help of a filter paper, tissues were weighed and chopped with scissors. The resulting minced tissues were homogenized in homogenization solution containing 3 mM EDTA pH 7.8, 50 mM Tris-HCl, pH7.5, 0.3 mM  $\epsilon$ -ACA, 0.5 mM PMSF, 0.15mM BTH, %10 glycerol and % 0.15 Triton X-100 at a volume of equal to 3 times of weight of liver by using Potter-Elvehjem glass homogenizer coupled with a motor-driven teflon pestle at 2 600 rpm. Ten passes were made for the homogenization of liver tissue. The resulting liver homogenate was centrifuged at 1500 x g for 10 minutes to obtain S1.5 fraction. The supernatant fraction (S1.5 fraction) was removed and stored at -80 °C until use in determination of protein expressions of the mitochondrial enzymes.

## 2.2.4. Determination of Protein Concentrations

Protein concentrations of S1.5 fractions were determined according to the method of Lowry *et al.* (1951) using crystalline bovine serum albumin as a standard.

This method depends on the reactions of copper ions with the peptide bonds under alkaline conditions and the reduction of Folin reagent to heteropolymolybdenum blue by the copper-catalyzed oxidation of aromatic amino acids (Lowry *et al.*, 1951).

### Reagents:

Reagent I: 2% (w/v)  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$

Reagent II: 2% (w/v) Na-K tartarate ( $\text{NaKC}_4\text{H}_4\text{O}_6$ )

Reagent A: 2% (w/v)  $\text{Na}_2\text{CO}_3$  in 0.1 N NaOH

Lowry Alkaline C upper Reagent (ACR): Reagent I, Reagent II and Reagent A are mixed in the same order with the ratio of 1:1:100.

Folin-phenol reagent: 2 N Stock Folin reagent is diluted to 1 N with distilled water (store in dark bottle).

Bovine Serum Albumin (BSA) Protein Standard: 0.02, 0.05, 0.10, 0.15, 0.20 mg/mL

Protein Sample: Rat liver S1.5 fractions

Rat liver S1.5 fractions were initially diluted 200 times. After initial dilutions, dilutions within test tubes were performed by taking aliquots of 0.1 mL, 0.25 mL, and 0.5 mL from the initially diluted samples into the test tubes. Their volumes were then completed to a final volume of 0.5 mL with distilled water. 10 mL of 1mg/mL BSA stock solution was prepared by dissolving 10 mg BSA in 10 mL distilled water. Serial dilutions were done to prepare other concentrations of BSA. The BSA standards with 5 different



concentrations, distilled water as a blank, and samples were put into the tubes. 2.5 mL of Lowry ACR was added to each tube and mix. The tubes were incubated for 10 minutes at room temperature for copper reaction in alkaline medium. 0.25 mL of Folin reagent was added and the tubes were mixed during 8 seconds by vortex. Reaction mixture for each tube was indicated in Table 2.1. The tubes were further incubated for 30 minutes at room temperature. After the incubation, the absorbance of each tube was read at 660 nm by using spectrophotometer. A standard curve was drawn by using absorbance readings of standards and slope of this curve was used for the calculation of protein amounts in the samples.

Protein concentration will be calculated by the following formula:

$$\text{Protein Concentration (mg/ml)} = \frac{\text{OD}_{660 \text{ nm}}}{\text{Slope of Standards}} \times \text{Dilution}_{\text{in tubes}} \times \text{Dilution}_{\text{initial}}$$

**Table 2. 1** The reaction mixture of tubes prepared for determination of protein concentrations.

<b>Tube Number</b>	<b>Standards (mL)</b>	<b>dH<sub>2</sub>O (mL)</b>	<b>Sample (mL)</b>	<b>Lowry ACR (mL)</b>	<b>Folin (mL)</b>
<b>Blank</b>	---	0.5	---	2.5	0.25
<b>Standard 1 (0.02 mg/mL)</b>	0.5	---	---	2.5	0.25
<b>Standard 2 (0.05 mg/mL)</b>	0.5	---	---	2.5	0.25
<b>Standard 3 (0.10 mg/mL)</b>	0.5	---	---	2.5	0.25
<b>Standard 4 (0.15 mg/mL)</b>	0.5	---	---	2.5	0.25
<b>Standard 5 (0.20 mg/mL)</b>	0.5	---	---	2.5	0.25
<b>Sample</b>	---	0.4	0.1	2.5	0.25
<b>Sample</b>	---	0.25	0.25	2.5	0.25
<b>Sample</b>	---	---	0.5	2.5	0.25

## **2.2.5. Determination of protein expression**

### **2.2.5.1. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE):**

Western blot analysis described by Towbin *et al.* (1979) was used for the analysis of protein expression levels of control and plant treated rat liver enzymes. Before blotting, proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) using 4% stacking gel and 7.5% separating gel in a discontinuous buffer system as described by Laemmli (1970). Separating and stacking gel solutions were prepared according to Table 2.2 as indicated order.

**Table 2. 2** Constituents of separating and stacking gel solutions.

Constituents	Separating Gel Solution	Stacking Gel Solution
<b>Monomer Concentration</b>	7,5 %	4%
<b>Gel solution (mL)</b>	7.5	1.3
<b>dH<sub>2</sub>O (mL)</b>	14.53	6.1
<b>Separating gel buffer (mL)</b>	7.5	-----
<b>Stacking gel buffer (mL)</b>	-----	2.5
<b>10 % SDS (mL)</b>	0.3	0.1
<b>10% ammonium per sulfate (mL)</b>	0.15	0.05
<b>TEMED (mL)</b>	0.03	0.02
<b>Total volume (mL)</b>	<b>30</b>	<b>10</b>

**Reagents:**

Gel Solution Acrylamide and N'-N'-Bis-Methylene-Acrylamide (Stock)

14.6 g of Acrylamide and 0.4 g of N'-N'-Bis-Methylene-Acrylamide were dissolved separately, mixed and filtered through filter paper. The volume was completed to 50 mL with distilled water.

Separating Buffer (1.5 M Tris-HCl, pH 8.8)

18.15 g of Tris-base was dissolved with distilled water and titrated with 10 M HCl to pH 8.8. The volume was completed to 100 mL with distilled water. The pH of the solution was checked at the end whether it is stable at pH 8.8.

Stacking Buffer (0.5 M Tris-HCl, pH 6.8)

6 g of Tris-base was dissolved with distilled water and titrated with 10 M HCl to pH 6.8. The volume was completed to 100 mL with distilled water. The pH of the solution was checked at the end whether it is stable at pH 6.8.

Sodium Dodecyl Sulfate SDS (10%)

1 g of SDS was dissolved in distilled water. The volume was completed to 10 mL.

Ammonium per sulfate APS: (10%, Fresh)

20 g of APS per gel was dissolved in 200  $\mu$ L of distilled water for each.

Tetramethylethylenediamine (TEMED) (Commercial)

Sample Dilution Buffer (SDB) (4x)

2.5 mL of 1 M Tris-HCl buffer (pH 6.8), 4 mL of Glycerol, 0.8 g of SDS, 2 mL of  $\beta$ -Mercaptoethanol and 0.001 g Bromophenol Blue were used, and the volume was completed to 10 mL with distilled water.

Electrophoretic Running Buffer (ERB) 0.25 M Tris, 1.92 M Glycine (10x Stock, diluted to 1x before use by adding 0.1% SDS)

After dissolving of 15 g of Tris-Base in 350 mL distilled water, 72 g of Glycine was added. They were mixed and the volume was completed to 500 mL with distilled water.

It was prepared as 10x stock solution and it was diluted to 1x and 1 g of SDS was added per liter of 1x buffer before use.

Vertical slab gel electrophoresis was performed by using Scie-plasV10-CDC vertical electrophoresis unit (Southam, England). Sandwich unit of module was set up by using two glass plates. Before use, acetone was used for cleaning. Just after preparation of separating gel solution indicated in Table 1, 4250  $\mu\text{L}$  of separating gel solution was poured into the sandwich unit, and 750  $\mu\text{L}$  of alcohol was added at the top of separating gel. The alcohol provides smooth gel surface and fast polymerization since it prevents the contact of the gel with air. It also removes the air bubbles. After the polymerization of separating gel, the alcohol was removed and the stacking gel solution was poured and the comb was placed. The combs were removed without giving damage to the gel after the polymerization of stacking gel. The wells were filled out with 1x ERB and cleaned up by a syringe to remove air bubbles and remaining gel particles which were not polymerized properly.

To get the 2 mg/mL concentration, the proteins were diluted with distilled water according to the following formula:

$$V = \frac{[\textit{protein concentration}]}{2.666} \times 20 - 20$$

$V$  is the volume of distilled water to be added to dissolve 20  $\mu\text{L}$  of sample.

After mixing 25  $\mu\text{L}$  of 4x sample dilution buffer with 75  $\mu\text{L}$  diluted sample, the samples were boiled in water bath for 1.5 minutes. Then, the samples were taken from water bath and each sample was loaded on different well by using Hamilton syringe. 3  $\mu\text{L}$  of protein ladder was loaded as marker. The buffer tank was filled with electrode running buffer and gel-running module was placed in it. The tank was connected to the Bio-Rad power supply and electrophoresis was run at 150 V and 15 mA for 40 minutes for stacking and 300 V and 30 mA for 2 hours in separating of the proteins.

## 2.2.5.2. Western blotting:

### Reagents:

Transfer Buffer 25 mM Tris, 192 mM Glycine

3.03 g of Trisma-base and 14.4 g of Glycine were dissolved in 200 mL of Methanol (20% v/v), and the volume was completed to 1 L with distilled water.

Tris-Buffered Saline and Tween 20 (TBST): 20 mM Tris-HCl pH 7.4, 500 mM NaCl, and 0.05% Tween 20 (Fresh)

9.5 g of NaCl was dissolved in some water; 6.5 mL of 1 M Tris-HCl Buffer pH 7.4 was added. 165  $\mu$ L of Tween 20 was added, and finally the volume was completed to 350 mL with distilled water.

Blocking Solution: 5% Non-Fat Dry Milk (Stock)

5 g Non-Fat Dry Milk was dissolved in 100 mL Tris-buffered saline (TBS).

Primary Antibody: 1/1000 dilution in blocking solution

Secondary Antibody: 1/2000 dilution in blocking solution

Substrate Solution: (Fresh, Light Sensitive)

Solution A: 2.67 mL of 1.5 M Tris-HCl Buffer (pH 8.8), 4 mL of 1 M NaCl, 96  $\mu$ L of Diethanolamine, 820  $\mu$ L of 100 mM MgCl<sub>2</sub>, 40  $\mu$ L of 100 mM ZnCl<sub>2</sub>, and 12.2 mg of Nitrotetrazolium Blue Chloride (NBT) were mixed and titrated with saturated Tris to pH 9.55. Then the volume was completed to 40 mL with distilled water. The pH of the solution was controlled at the end.


Solution B: 2 mg of Phenazine Methosulfate was dissolved in 1 mL of distilled water.

Solution C: 5.44 mg of 5-bromo 4-chloro 3-indoyl phosphate (BCIP) was dissolved in 136  $\mu$ L of N-N-dimethylformamide.

To prepare the substrate solution, 20 mL of Solution A, 68  $\mu$ L of Solution C, and 134  $\mu$ L of Solution B were mixed for each membrane and used immediately.

To remove the buffer salts coming from electrophoretic running buffer and SDS as well as the preparation of the gels for transfer system, the gels were placed into transfer buffer for 10 minutes after SDS PAGE. After 10 minutes, the gels were removed from glasses. Nitrocellulose membrane, two Whatman papers, gel, and two fiber pads were placed in transfer sandwich as shown in Figure 2.1. A test tube was used to remove any air bubbles between the layers by gently rolling over the sandwich. The transfer sandwich was placed into Mini Trans-Blot module 165-8033 (Bio-Rad Laboratories, Richmond, CA, USA) and module was filled with transfer buffer. The transfer was carried out at 90 volt and 400 mA for 90 minutes. After transfer, the nitrocellulose membranes were washed with TBST for 10 minutes to get rid of the buffer salts. Then, the nitrocellulose membrane was incubated with blocking solution in room temperature for an hour.






**Figure 2. 1** Western Blot sandwich.

After that, immunochemical staining of the separated proteins on nitrocellulose membrane was done by incubating in primary antibody which is diluted 1000 times in blocking solution for 2 hours by shaking. The membranes were further incubated with TBST three times each of which is 10 minutes to remove excess, unbound primary antibody. After removal of excess primary antibody, the membranes were incubated

with secondary antibody which is 2000 times diluted alkaline phosphatase conjugated mouse anti-goat IgG for 1 hour. After 1 hour, the membrane was washed again with TBST. The final step was the preparation of the substrate solution. As soon as it was prepared as described by Ey and Ashman (1986) to visualize the specifically bound antibodies (Figure 2.2), the membrane was incubated with the substrate solution. The final images were scanned and ImageJ visualization software developed by NIH was used to quantitatively analyze the final images.



**Figure 2. 2** Detection of immunoreactive bands in Western blots.

## **2.2.6. Determination of mRNA expression**

### **2.2.6.1. Isolation of total RNA from rat liver tissues**

#### **Reagents:**

Diethylpyrocarbonate (DEPC) Water: %0.1 (v/v)

1 mL of DEPC was mixed with 1 L of distilled water.

TRIZol<sup>®</sup>: It is the brand name of the product from Invitrogen, and the brand name from MRC.

Chloroform: Stock, Stored at -20 °C

Isopropanol: Stock, Stored at -20°C

75% Ethanol: Stock, Stored at -20°C

At the beginning of the experiment, all equipments were treated with Diethylpyrocarbonate (DEPC) water in order to inhibit RNase activity. After the evaporation of excess DEPC, they were autoclaved.

50 mg of rat tissue was minced and homogenate with 500 µL of TRIZol<sup>®</sup> in a glass-Teflon homogenizer for 15 seconds 2-3 times. Extra 10 µL of TRIZol<sup>®</sup> was added for further 1 mg of tissue. The homogenate tissue was transferred into an eppendorf tube and put into liquid nitrogen to make it frozen. Before complete melting, 100 µL of chloroform was added and vortexed for one minute and incubated at room temperature for 5 minutes. Then, it was incubated in ice for 5 minutes. After the incubation periods, the homogenate was centrifuged at 13000 rpm for 15 minutes at 4 °C. The uppermost layer of the three phases formed after centrifugation was taken and same volume of

isopropanol was added. It was gently mixed. The mixture was incubated at room temperature for 10 minutes. It is centrifuged at 13000 rpm for 5 minutes at 4 °C again, the supernatant was discarded and the pellet was mixed with 1 mL of 75% ethanol. The mixture was centrifuged again at 7500 rpm for 5 minutes at 4 °C; the pellet was taken and dried in hood. Finally, RNA was dissolved in 75 µL of Nuclease-free distilled water and used for further studies. It was kept at -80 °C before using.

### **2.2.6.2. Determination of RNA concentration**

#### **Reagents:**

Tris-EDTA (TE) Buffer: 100 mM Tris, 10 mM EDTA, pH 8.0

RNA molecules give maximum absorbance at 260 nm, so reading absorbance at 260 nm was used to calculate the concentration of nucleic acid in the sample. Also, the ratio between OD values at 260 nm and 280 nm ( $OD_{260}/OD_{280}$ ) was used to estimate the purity of RNA molecules. 7 µL of RNA solution was mixed with 693 µL of TE buffer in quartz cuvettes and the absorbances at 260 and 280 nm were measured spectrophotometrically. The ratio of  $OD_{260}/OD_{280}$  must be between 1.8 and 2.2. The optical density of 1.0 corresponded to 40 µg/mL for RNA, so RNA concentration will be calculated according to the following formula:

$$\text{RNA } (\mu\text{g/ml}) = OD_{260} \times \text{DF} \times 40 \mu\text{g RNA /ml (1 } OD_{260} \text{ unit)}$$

### **2.2.6.3. Qualification of RNA molecules by agarose gel electrophoresis**

#### **Reagents:**

Tris-Borate-EDTA (TBE) Buffer: 0.5 x, pH 8.3

Loading Buffer: 0.25% bromophenol blue, 0.25 % xylene cyanol FF, 15% Ficoll

Presence of RNA was checked on 1 % (w/v) agarose gel by using horizontal agarose gel electrophoresis unit. 1 % (w/v) agarose was prepared by melting 1 g of agarose within 100 mL 0.5 X TBE buffer in microwave oven. The solution was cooled approximately 60 °C. 7 µL of ethidium bromide solution (10 mg/ml) was added and the solution was mixed well. Agarose gel solution was poured into electrophoresis tray and comb was placed to form wells. After the polymerization, gel tank was filled with 300 mL of 0.5 X TBE buffer and the comb was removed. 10 µL of RNA solution was mixed with 2 µL of loading buffer and 2 µL of glycerol; the mixture was loaded into the wells. Electrophoresis was carried out at 100 V and 500 mA for 45 minutes. The gel was observed and the photographed under UV light.

### **2.2.6.4. cDNA synthesis**

#### **Reagents:**

Reaction Buffer: 250 mM Tris-HCl pH 8.3, 250 mM KCl, 20 mM MgCl<sub>2</sub> and 50 mM DDT

M-MuLV-RT: Reverse Transcriptase

Reverse transcription is the process by which cDNA is synthesized from RNA template. For cDNA synthesis, 2.5-5 µg of total RNA isolated from rat liver and 0.5 µg (1 µL

from 500 µg/mL stock) of oligo dT primers will be mixed in an eppendorf tube. Due to the variation of RNA concentrations, volume of RNA is variable, too. Therefore, final volume will be completed 12 µL with DEPC treated water. The solution was mixed gently and spinned down in microfuge. Mixture was incubated at 70 °C for 5 minutes, then it was chilled on ice and the drops were collected by microfuge. After that, 4 µL of 5X reaction buffer, 1 µL Ribolock and 2 µL of 10 mM dNTP were added successively. The tube was mixed gently and the drops again were collected by microfuge. It was incubated at 37 °C for 5 minutes. After incubation, 1 µL of M-MuLu-RT was added and incubated at 42 °C for 1 hour. Finally, the reaction was stopped by keeping at 70 °C for 10 min and chilled on ice. cDNA was stored at -20 °C for further use.

#### **2.2.6.5. Quantitative real-time PCR**

Quantitative real-time PCR assays for rat mRNA expressions were carried out using Light Cycler 1.5. Reactions took place in reaction mixture by using Light Cycler-Fast Start DNA Master<sup>Plus</sup> SYBR Green I.

20 µL reaction mixture was composed of 7.5 µL of PCR-grade water, 0.5 µL of forward and 0.5 µL reverse primers (Table 2.3) whose sequences are indicated in table, and 12.5 µL of master mix containing Fast Start Taq DNA Polymerase, MgCl<sub>2</sub>, SYBR Green I dye and dNTP mix. 5 µL of cDNA was added to a total reaction mixture of 20 µL. No template control which contains PCR-grade water instead of cDNA sample was used in every RT-PCR run to check whether there is contamination in the components of the reaction mixture.

The following Light Cycler run protocol was used:

- Preincubation program at 95 °C for 10 minutes in order to activate Taq polymerase and denature DNA
- Amplification and quantification program repeated 45 times

- 95 °C for 20 seconds
- 54-57 °C annealing (depending on the gene) for 30 seconds
- 72 °C extension for 30 seconds with a single fluorescence measurement
- Melting curve program 65-95 °C with a heating rate of 0.1 °C/s and continuous fluorescence measurement
- Cooling step to 40 °C for 30 seconds.

Melting curve analysis of the amplification product was done at the end of each amplification reaction to confirm the detection of a single PCR product. Quantities of specific mRNAs in the sample were measured according to the corresponding gene specific relative standard curve derived from dilution series of a control cDNA (1:10, 1:100, 1:500, 1:1000, and 1:5000) and expression level of the target genes was measured relative to housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Light Cycler quantification software was used to draw the standard curve from the dilution series of a control cDNA.

**Table 2. 3** Primer sequences, annealing temperatures and product sizes.

Gene	Forward Primer (5'→3')	Reverse Primer (5'→3')	Annealing Temperature (°C)	Product Size (bp)
<b>CYP27B1</b>	GAGATCACAGGCGCTGTGAAC	TCCAACATCAACACTTCTTTGATCA	55	107
<b>CYP24A1*</b>	TGGATGAGCTGTGCGATGA	TGCTTTCAAAGGACCACTTG TTC	59	75
<b>CYP24A1*</b>	TTGAAAGCATCTGCCTTGTGT	GTCACCATCATCTTCCCAAAC	57	130
<b>GAPDH</b>	TGATGACATCAAGAAGGTGGTGAAG	TCCTTGGAGGCCATGTGGGCCAT	55	240

\*Two different sets of primers were used for CYP24A1 gene.



### **2.2.7. Statistical Analysis**

Statistical analyses were performed by using GraphPad Prism version 5 statistical software package for Windows. All results were expressed as means with their Standard Deviation (SD) or Standard Error Mean (SEM). Unpaired, two-tailed student's *t*-test and  $p < 0.05$  were chosen as the level for significance.

## CHAPTER 3

### RESULTS

#### 3.1. Protein concentrations of rat liver S1.5 fractions

The animals used in this study were divided into three groups: Control (C) group with no injection, *Epilobium hirsutum*-treated (EHT) and *Viscum album*-treated (VAT) groups. EHT and VAT groups were injected with 37.5 mg water extract of *Epilobium hirsutum* L./kg body weight/day and 10 mg water extract of *Viscum album* L. /kg body weight/day, respectively. Control, EHT and VAT groups were composed of 11, 25 and 15 animals, respectively. The S1.5 fractions were prepared by centrifugation after homogenization of the livers. Average protein concentrations of control and extract-treated rat liver S1.5 fractions were determined and they are listed in Table 3.1.

**Table 3. 1** Average protein concentrations of rat liver S1.5 fractions.

Group	Average Protein Concentration (mg/mL)
Control (N=11)	36.15±5.56
<i>Epilobium hirsutum</i> -treated (N=25)	33.89±9.19
<i>Viscum album</i> -treated (N=15)	46.19±15.07


### **3.2. Effects of *Epilobium hirsutum* L. on CYP24A1 and CYP27B1 protein expression**

Rat liver mitochondrial CYP24A1 and CYP27B1 protein expressions of control and *Epilobium hirsutum*-treated groups were determined by using Western blotting technique following the separation of proteins in S1.5 fractions by SDS-PAGE. Immunochemical detection of liver mitochondrial CYP24A1 and CYP27B1 proteins were performed by incubating the nitrocellulose membrane in diluted rabbit polyclonal primary antibodies and then secondary antibody, alkaline phosphatase-conjugated goat anti-rabbit IgG.


#### **3.2.1. Effect of *Epilobium hirsutum* L. on CYP24A1 protein expression**

Monomer molecular weight of CYP24A1 is known as 65 kDa and Figure 3.1 shows the exact position of CYP24A1 on nitrocellulose membrane.  $\beta$ -actin with molecular weight of 42 kDa is used as an internal standard and protein loading control. The intensity of immunoreactive protein bands of both control and EHT animals were analyzed by using ImageJ visualization software. Figure 3.2 shows the relative protein expressions where mean of protein expressions of control group was taken as  $100 \pm 8.37$  (N=11) and then mean protein expression of *Epilobium-hirsutum*-treated group was calculated as  $69 \pm 10.29$  (N=25). As illustrated in Figure 3.2, rat liver mitochondrial CYP24A1 protein expression decreased in EHT group compared to control group (unpaired, two-tailed student's *t*-test,  $p < 0.0001$ ). The mean CYP24A1 protein expression of EHT group was found as 69% of the mean of control group.


### A. CYP24A1



### B. $\beta$ -actin



**Figure 3. 1** (A) Immunoreactive protein bands of control (N=11) and *Epilobium hirsutum* L.-treated (N=25) groups representing CYP24A1 (MW of 65 kDa). (B)  $\beta$ -actin (MW of 42 kDa) was used as internal control for each membrane.




**Figure 3. 2** *In-vivo* effect of *Epilobium hirsutum* L. on CYP24A1 protein expression. The band quantifications are expressed as mean  $\pm$ SD of the relative intensity. The mean relative protein expression of *Epilobium hirsutum* L.-treated group is 69% of the mean of control group. The *p* value obtained from unpaired, two-tailed student's *t*-test is less than 0.0001.

### 3.2.2. Effect of *Epilobium hirsutum* L. on CYP27B1 protein expression


Monomer molecular weight of CYP27B1 is known as 54 kDa and Figure 3.3 shows the exact position of CYP27B1 on nitrocellulose membrane.  $\beta$ -actin is used as internal standard (Molecular weight of  $\beta$ -actin is 42 kDa). The intensity of immunoreactive

protein bands of control and EHT animals were analyzed by using ImageJ visualization software. Figure 3.4 shows the relative protein expressions where mean of protein expressions of control group was taken as  $100 \pm 19.32$  (N=11) and then mean protein expression of *Epilobium-hirsutum*-treated group was calculated as  $82 \pm 12.78$  (N=25). As illustrated in Figure 3.4, rat liver mitochondrial CYP27B1 protein expression decreased in EHT group compared to control group (unpaired, two-tailed student's *t*-test,  $p < 0.05$ ). The mean CYP27B1 protein expression of EHT group was found as 82% of the mean of control group.


### A. CYP27B1



### B. $\beta$ -actin



**Figure 3. 3** (A) Immunoreactive protein bands of control (N=11) and *Epilobium hirsutum* L.-treated (N=25) groups representing CYP27B1 (MW of 54 kDa). (B)  $\beta$ -actin (MW of 42 kDa) was used as internal control for each membrane.



**Figure 3. 4** *In-vivo* effect of *Epilobium hirsutum* L. on CYP27B1 protein expression. The band quantifications are expressed as mean  $\pm$ SD of the relative intensity. The mean relative protein expression of *Epilobium hirsutum* L.-treated group is 82% of the mean of control group. The *p* value obtained from unpaired, two-tailed student's *t*-test is less than 0.028.


### **3.3. Effect of *Epilobium hirsutum* L. on CYP24A1 and CYP27B1 mRNA expression**

#### **3.3.1. Quality control of RNA molecules by agarose gel electrophoresis**

Total RNA was isolated from rat liver tissue as described in Materials & Methods part. Due to the risk of DNA contamination, RNA isolation was one of the most critical parts




of the experiments. Qualities of RNA molecules were checked with  $OD_{260}/OD_{280}$  ratio which must be between 1.8 and 2.2.  $OD_{260}/OD_{280}$  ratio of the samples was good enough to be used in cDNA synthesis and real-time PCR studies. After that, 28S and 18S RNA bands were checked with agarose gel electrophoresis. RNA molecules having  $OD_{260}/OD_{280}$  between 1.8 and 2.2 showed intact and well-separated 28S and 18S RNA bands after agarose gel electrophoresis as shown in Figure 3.5.




**Figure 3. 5** Agarose gel electrophoresis pattern of RNA samples isolated from rat liver tissues.

### **3.3.2. Effect of *Epilobium hirsutum* L. on CYP24A1 mRNA expression**

qRT-PCR technique was used to determine the mRNA expression of CYP24A1. For the beginning, serial optimization was done with samples from the control group. For the optimization part, different primer pairs and cDNA concentrations were used. For the annealing, the temperatures between 45 °C and 60 °C were tested. Also, qRT-PCR of GAPDH used as internal control (housekeeping gene) was done to eliminate the possible risks of contamination which may come from the cDNA samples, SYBR-green and water. To eliminate the contamination risk of primers, no template control which included water instead of cDNA samples was used. These optimization steps were done at different annealing temperatures with different cycle points. Also, two different primer sets specific for *CYP24A1* gene were tested. However, no consistent results were obtained probably due to the undetectable properties of CYP24A1 mRNA in the liver. Two of the melting curves generated from the optimization experiments are shown in Figures 3.6 and 3.7. In Figure 3.6, 55 °C was used as annealing temperature, but it caused the formation of primer dimer. To get rid of primer dimer, annealing temperature was increased, but still no meaningful results were obtained as represented in Figure 3.7.



**Figure 3. 6** Melting curve showing the fluorescence of SYBR green dye I versus temperature. 55 °C was used as annealing temperature.




**Figure 3. 7** Melting curve showing the fluorescence of SYBR green dye I versus temperature. 60 °C was used as annealing temperature.


### 3.3.3. Effect of *Epilobium hirsutum* L. on CYP27B1 mRNA expression

qRT-PCR technique was used to determine the mRNA expression of CYP27B1. GAPDH was used as internal control to calculate the relative mRNA expression of *Epilobium hirsutum*-treated CYP27B1. The specific annealing temperatures of the primers of CYP27B1 and GAPDH were used in qRT-PCR.


mRNA expressions of CYP27B1 were determined by using qRT-PCR and relative expressions of CYP27B1 of control and treated animals were calculated using GAPDH as internal control (housekeeping gene). Figure 3.8 shows the standard curve which was generated from 1:10, 1:100, 1:500, 1:1000, and 1:5000 diluted cDNAs used for quantifications of the samples. Figure 3.9 illustrates the amplification plot showing the changes in fluorescence of SYBR green dye I versus cycle number of rat liver CYP27B1 gene of control and *Epilobium hirsutum*-treated samples. In Figure 3.10, melting curve with one peak is represented for the detection of single PCR product.



**Figure 3. 8** Standard curve derived from dilution series of a control cDNA to measure quantities of specific CYP27B1 mRNAs in the sample.




**Figure 3. 9** Amplification plot showing the changes in fluorescence of SYBR green dye I versus cycle number of rat liver CYP27B1 gene of control and *Epilobium hirsutum*-treated samples.




**Figure 3. 10** Melting curve showing the fluorescence of SYBR green dye I versus temperature. One peak in the melting curve confirms the detection of single PCR product.

In Figures 3.11 and 3.12, the PCR products of CYP27B1 and GAPDH are represented, respectively. The band patterns in gels confirm the exact position of CYP27B1 and GAPDH products produced in qRT-PCR which are 107 and 240 bp, respectively. The results obtained using Rotor-Gene 1.7.87 quantitation software were normalized with GAPDH (housekeeping gene) and the Livak method (Livak & Schmittgen, 2001) was used to determine relative CYP27B1 mRNA expression change when animals injected by plant extract. Table 3.2 gives the Livak ( $2^{-\Delta\Delta Ct}$ ) method for calculation of relative mRNA expression using Ct values.



**Figure 3. 11** qRT-PCR product of liver CYP27B1 cDNA (107 bp) of control and *Epilobium hirsutum*-treated animals. Each lane contains 10  $\mu$ L of qRT-PCR Product.




**Figure 3. 12** qRT-PCR product of liver GAPDH cDNA (240 bp) of control and *Epilobium hirsutum*-treated animals. Each lane contains 10  $\mu$ L of qRT-PCR Product.

**Table 3. 2** The Livak ( $2^{-\Delta\Delta Ct}$ ) method for the calculation of relative mRNA expression using Ct values.

	<b>Control</b>	<b>EHT</b>		
<b>Ct<sub>CYP27B1</sub></b>	32.03	31.31		
<b>Ct<sub>GAPDH</sub></b>	18.25	18.97		
<b><math>\Delta Ct_{EHT} =</math></b>	<b>Ct<sub>GAPDH</sub></b>	<b>-</b>	<b>Ct<sub>CYP27B1</sub></b>	
<b><math>\Delta Ct_{reference} =</math></b>	<b>Ct<sub>GAPDH</sub></b>	<b>-</b>	<b>Ct<sub>CYP27B1</sub></b>	
<b><math>\Delta Ct_{EHT} =</math></b>	18.97	<b>-</b>	31.31	<b>= -12.34</b>
<b><math>\Delta Ct_{reference} =</math></b>	18.25	<b>-</b>	32.03	<b>= -13.78</b>
	<b><math>\Delta\Delta Ct = \Delta Ct_{reference} - \Delta Ct_{EHT}</math></b>			<b>= -1.44</b>
<b><math>2^{-\Delta\Delta Ct}</math></b>	<b>=</b>	<b>2.7</b>		

The normalized average liver CYP27B1 mRNA level of control animals was found to be  $1.45 \pm 0.27$  (mean  $\pm$  SEM, N=11). The average CYP27B1 mRNA amount was calculated as  $3.91 \pm 0.49$  (mean  $\pm$  SEM, N=25) for liver tissue of *Epilobium hirsutum*-treated animals. As shown in Figure 3.13, *Epilobium hirsutum* treatment of animals caused 2.7 fold increase in mRNA expression with respect to control group ( $p < 0.005$ , unpaired, two-tailed student's *t*-test).



**Figure 3. 13** *In vivo* effect of *Epilobium hirsutum* L. on rat liver CYP27B1 mRNA expression. The quantities are expressed as mean  $\pm$ SEM of the relative expression. Relative mRNA expression of *Epilobium hirsutum* L-treated group is 2.7 fold higher than that of control group. The *p* value obtained from unpaired, two-tailed student's *t*-test was 0.0017.




### **3.4. Effect of *Viscum album* L. on CYP24A1 and CYP27B1 protein expression**

Rat liver mitochondrial CYP24A1 and CYP27B1 protein expressions of control and *Viscum album*-treated groups were determined by using Western blotting technique following the separation of proteins in S1.5 fractions by SDS-PAGE. Immunochemical detection of liver mitochondrial CYP24A1 and CYP27B1 proteins were performed by incubating the nitrocellulose membrane in diluted rabbit polyclonal primary antibodies and then secondary antibody, alkaline phosphatase-conjugated goat anti-rabbit IgG.


#### **3.4.1. Effect of *Viscum album* L. on CYP24A1 protein expression**

Monomer molecular weight of CYP24A1 is known as 65 kDa and Figure 3.14 shows the exact position of CYP24A1 on nitrocellulose membrane.  $\beta$ -actin with a molecular weight of 42 kDa is used as an internal standard and protein loading control. The intensity of immunoreactive protein bands of both control and EHT animals were analyzed by using ImageJ visualization software. Figure 3.15 shows the relative protein expressions where mean of protein expressions of control group was found as  $100 \pm 16.93$  (N=11) and then mean protein expression of *Viscum album*-treated group was calculated as  $83 \pm 13.49$  (N=15). As illustrated in Figure 3.6, rat liver mitochondrial CYP24A1 protein expression decreased in EHT group compared to control group (unpaired, two-tailed student's *t*-test,  $p < 0.05$ ). The mean CYP24A1 protein expression of EHT group was found as 83% of the mean of control group.


### A. CYP24A1



### B. $\beta$ -actin



**Figure 3. 14** (A) Immunoreactive protein bands of control (N=11) and *Viscum album* L.-treated (N=15) groups representing CYP24A1 (MW of 65 kDa). (B)  $\beta$ -actin (MW of 42 kDa) was used as internal control for each membrane.




**Figure 3. 15** *In-vivo* effect of *Viscum album* L. on CYP24A1 protein expression. The band quantifications are expressed as mean  $\pm$ SD of the relative intensity. The mean relative protein expression of *Viscum album* L.-treated group is 83% of the mean of control group. The *p* value obtained from unpaired, two-tailed student's *t*-test is less than 0.014.

### 3.4.2. Effect of *Viscum album* L. on CYP27B1 protein expression


Monomer molecular weight of CYP27B1 is known as 54 kDa and Figure 3.16 shows the exact position of CYP27B1 on nitrocellulose membrane.  $\beta$ -actin is used as internal standard (Molecular weight of  $\beta$ -actin is 42 kDa). The intensity of immunoreactive protein bands of control and EHT animals were analyzed by using ImageJ visualization software. Figure 3.17 shows the relative protein expressions where mean of protein expressions of control group was found as  $100 \pm 15.19$  (N=11) and then mean protein expression of *Viscum album*-treated group was calculated as  $82 \pm 15.57$  (N=15). As

illustrated in Figure 3.8, rat liver mitochondrial CYP27B1 protein expression decreased in EHT group compared to control group (unpaired, two-tailed student's *t*-test,  $p < 0.05$ ). The mean CYP27B1 protein expression of EHT group was found as 82% of the mean of control group.


### A. CYP27B1



### B. $\beta$ -actin



**Figure 3. 16** (A) Immunoreactive protein bands of control (N=11) and *Viscum album* L.-treated (N=15) groups representing CYP27B1 (MW of 54 kDa). (B)  $\beta$ -actin (MW of 42 kDa) was used as internal control for each membrane.




**Figure 3. 17** *In-vivo* effect of *Viscum album* L. on CYP27B1 protein expression. The band quantifications are expressed as mean  $\pm$ SD of the relative intensity. The mean relative protein expression of *Viscum album* L.-treated group is 82% of the mean of control group. The *p* value obtained from unpaired, two-tailed student's *t*-test is less than 0.013.

### 3.5. Effect of *Viscum album* L. on CYP24A1 and CYP27B1 mRNA expression

#### 3.5.1. Quality control of RNA molecules by agarose gel electrophoresis

Total RNA was isolated from rat liver tissue as described in Materials & Methods part. Due to the risk of DNA contamination, RNA isolation was one of the most critical parts of the experiments. Qualities of RNA molecules were checked with OD<sub>260</sub>/OD<sub>280</sub> ratio which must be between 1.8 and 2.2. OD<sub>260</sub>/OD<sub>280</sub> ratio of the samples was good enough to be used in cDNA synthesis and real-time PCR studies. After that, 28S and 18S RNA bands were checked with agarose gel electrophoresis. RNA molecules having

OD<sub>260</sub>/OD<sub>280</sub> between 1.8 and 2.2 showed intact and well-separated 28S and 18S RNA bands after agarose gel electrophoresis as shown in Figure 3.18.




**Figure 3. 18** Agarose gel electrophoresis pattern of RNA samples isolated from rat liver tissues.


### **3.5.2. Effect of *Viscum album* L. on CYP24A1 mRNA expression**

qRT-PCR technique was used to determine the mRNA expression of CY24A1. For the beginning, serial optimization was done with samples from the control group. For the optimization part, different primer pairs and cDNA concentrations were used. For the annealing, the temperatures between 45 °C and 60 °C were tested. Also, qRT-PCR of GAPDH used as internal control (housekeeping gene) was done to eliminate the possible risks of contamination which may come from the cDNA samples, SYBR-green and

water. To eliminate the contamination risk of primers, no template control which included water instead of cDNA samples was used. These optimization steps were done at different annealing temperatures with different cycle points. Also, two different primer sets specific for *CYP24A1* gene were tested. However, no consistent results were obtained probably due to the undetectable properties of *CYP24A1* mRNA in the liver. Two of the melting curves generated from the optimization experiments are shown in Figures 3.19 and 3.20.



**Figure 3. 19** Melting curve showing the fluorescence of SYBR green dye I versus temperature. 50 °C was used as annealing temperature.




**Figure 3. 20** Melting curve showing the fluorescence of SYBR green dye I versus temperature. 60 °C was used as annealing temperature.

### 3.5.3. Effect of *Viscum album L.* on CYP27B1 mRNA expression


qRT-PCR technique was used to determine the mRNA expression of CYP27B1. GAPDH was used as internal standard to calculate the relative mRNA expression of *Viscum album*-treated CYP27B1. The specific annealing temperatures of the primers of CYP27B1 and GAPDH were used in qRT-PCR.

Figure 3.21 shows the standard curve which was generated from 1:10, 1:100, 1:500, 1:1000, and 1:5000 diluted cDNAs used for quantifications of the samples. Figure 3.22 illustrates the amplification plot showing the changes in fluorescence of SYBR green dye I versus cycle number of rat liver CYP27B1 gene of control and *Viscum album*-treated samples. In Figure 3.23, melting curve with one peak is represented for the detection of single PCR product.






**Figure 3. 21** Standard curve derived from dilution series of a control cDNA to measure quantities of specific CYP27B1 mRNAs in the sample.



**Figure 3. 22** Amplification plot showing the changes in fluorescence of SYBR green dye I versus cycle number of control and *Viscum album*-treated rat livers' CYP27B1 gene.




**Figure 3. 23** Melting curve showing the fluorescence of SYBR green dye I versus temperature with one peak meaning single PCR product detection. One peak in the melting curve confirms the detection of single PCR product.

In Figures 3.24 and 3.25, the PCR products of CYP27B1 and GAPDH are represented, respectively. The figures confirm the exact position of CYP27B1 and GAPDH products produced in qRT-PCR.


mRNA expressions CYP27B1 were determined by using qRT-PCR and relative expressions of CYP27B1 of control and treated animals were calculated using GAPDH as internal control (housekeeping gene). Figure 3.21 shows the standard curve which was generated from 1:10, 1:100, 1:500, 1:1000, and 1:5000 diluted cDNAs used for quantifications of the samples. Figure 3.22 illustrates the amplification plot showing the changes in fluorescence of SYBR green dye I versus cycle number of control and

*Viscum album*-treated rat livers' CYP27B1 gene. In Figure 3.23, melting curve with one peak is represented for the detection of single PCR product.

In Figures 3.24 and 3.25, the PCR products of CYP27B1 and GAPDH are represented, respectively. The band patterns of the gels confirm the exact position of CYP27B1 and GAPDH products produced in qRT-PCR which are 107 and 240 bp, respectively. The results obtained using Rotor-Gene 1.7.87 quantitation software were normalized with GAPDH (housekeeping gene) and the Livak method (Livak & Schmittgen, 2001) was used to determine relative CYP27B1 mRNA expression change when animals injected by plant extract. Table 3.2 gives the Livak ( $2^{-\Delta\Delta Ct}$ ) method for calculation of relative mRNA expression using Ct values.



**Figure 3. 24** qRT-PCR product of liver CYP27B1 cDNA (107bp) of control and *Viscum album*-treated animals. Each lane contains 10  $\mu$ L of qRT-PCR Product.




**Figure 3.** 25 qRT-PCR product of liver GAPDH cDNA (240 bp) of control and *Viscum album*-treated animals. Each lane contains 10  $\mu$ L of qRT-PCR Product.

**Table 3. 3** The Livak ( $2^{-\Delta\Delta Ct}$ ) method for the calculation of relative mRNA expression using Ct values.

	Control	VAT		
<b>Ct<sub>CYP27B1</sub></b>	31.41	30.56		
<b>Ct<sub>GAPDH</sub></b>	17.45	18.52		
<b><math>\Delta Ct_{VAT} = Ct_{GAPDH} - Ct_{CYP27B1}</math></b>				
<b><math>\Delta Ct_{reference} = Ct_{GAPDH} - Ct_{CYP27B1}</math></b>				
<b><math>\Delta Ct_{VAT} =</math></b>	<b>18.52</b>	<b>-</b>	<b>30.56</b>	<b>= -12.04</b>
<b><math>\Delta Ct_{reference} =</math></b>	<b>17.45</b>	<b>-</b>	<b>31.41</b>	<b>= -13.96</b>
			<b><math>\Delta\Delta Ct = \Delta Ct_{reference} - \Delta Ct_{VAT}</math></b>	<b>= -1.92</b>
<b><math>2^{-\Delta\Delta Ct}</math></b>	<b>=</b>	<b>3.8</b>		

The normalized average liver CYP27B1 mRNA level of control animals was found to be  $1.44 \pm 0.23$  (mean  $\pm$  SEM, N=11). The average CYP27B1 mRNA amount was calculated as  $5.42 \pm 0.95$  (mean  $\pm$  SEM, N=15) for liver tissue of *Viscum album*-treated animals. As shown in Figure 3.26, *Viscum album* treatment of animals caused 3.8 fold increase in mRNA expression with respect to control group ( $p < 0.005$ , unpaired, two-tailed student's *t*-test).



**Figure 3. 26** *In vivo* effect of *Viscum album* L. on rat liver CYP27B1 mRNA expression. The quantifications are expressed as mean  $\pm$ SEM of the relative expression. Relative mRNA expression of *Viscum album* L-treated group is 3.8 fold higher than that of control group. The *p* value obtained from unpaired, two-tailed student's *t*-test was 0.0018.

## CHAPTER 4

### DISCUSSION

Plants possess primary importance in medicinal applications since they have numerous phytochemicals which are composed of a diverse range of biologically active compounds. These active compounds are the secondary plant metabolites showing pharmacological or toxicological effects in animals. Among these biologically active compounds; terpenoids, polyphenolics, glucosinolates, phytosterols and thiosulfanates are the most important phytochemicals. Phytochemicals display some beneficial health promoting impacts as antioxidants, blood pressure or blood sugar influencing substances, or agents with anti-inflammatory, anticarcinogenic, antithrombotic, immunity-supporting, cholesterol-lowering, antifungal, antibacterial or antiviral effects (Schreiner & Huyskens-Keil, 2006). For instance, ellagic acid is a natural polyphenol found in many plant species and has antimutagenic, antioxidant and anti-inflammatory activity in bacterial and mammalian systems (Vattem & Shetty, 2005).

Vitamin D<sub>3</sub>, also known as cholecalciferol, is an important compound which has essential biologic functions especially on calcium and bone metabolism. It is formed from 7-dehydrocholesterol by UV irradiation. To get the active form of vitamin D<sub>3</sub>, it has to be subjected to two successive hydroxylation reactions. First hydroxylation reaction is catalyzed by CYP27A1 while the latter is catalyzed by CYP27B1. On the other hand, CYP24A1 functions for the inactivation of vitamin D<sub>3</sub> compounds (Sakaki *et al.*, 2005).

CYP24A1 and CYP27B1 are the members of cytochrome P450 super-family and key enzymes involved in the metabolism of Vitamin D<sub>3</sub>. CYP24A1 and CYP27B1 are mitochondrial enzymes and also known as 24-hydroxylase and 25-hydroxyvitamin D<sub>3</sub> 1 $\alpha$ -hydroxylase, respectively. CYP27B1 involves in 1 $\alpha$ -hydroxylation of 25-OH-D<sub>3</sub> into 1,25-(OH)<sub>2</sub>D<sub>3</sub> while CYP24A1 involves in 24-hydroxylation of 25-OH-D<sub>3</sub> and 1,25-(OH)<sub>2</sub>D<sub>3</sub> which is required for the catabolism of vitamin D<sub>3</sub> compounds (Ohyama & Yamasaki, 2004; Prosser & Jones, 2004).

It is well known that both protein and mRNA expressions of P450 enzymes can be affected by physiological and pathophysiological conditions as well as diet (Arinc *et al.*, 2007). For instance, CYP27B1 is under tight regulation of 1,25-(OH)<sub>2</sub>D<sub>3</sub>, PTH and calcitonin. While 1,25-(OH)<sub>2</sub>D<sub>3</sub> down-regulates the gene expression of CYP27B1, PTH and calcitonin are the upregulators of CYP27B1 expression (Murayama *et al.*, 1998; Shinki *et al.*, 1999).

In this study, *in vivo* effects of water extracts of the medicinal plants *Epilobium hirsutum* L. and *Viscum album* L. on 24-hydroxylase (CYP24A1) and 1 $\alpha$ -hydroxylase (CYP27B1) protein and mRNA expressions were analyzed and demonstrated for the first time. For this purpose, 37.5 mg water extract of *Epilobium hirsutum* L./kg of body weight and 10 mg water extract of *Viscum album* L. /kg of body weight were injected to 30 and 15 Wistar albino rats, respectively, for 9 consecutive days. Then, decapitation of the animals was done and their livers were removed. After preparation of S1.5 fractions including mitochondrial enzymes, protein and mRNA expression analysis of hepatic CYP24A1 and CYP27B1 were performed to show the effects of these plants at both translational and transcriptional levels (Table 4.1).

**Table 4. 1** Summary of results of protein and mRNA expression analysis of hepatic CYP24A1 and CYP27B1 from control, EHT and VAT groups.

	CYP24A1		CYP27B1	
	Protein expression (% of control)	mRNA expression (% of control)	Protein expression (% of control)	mRNA expression (% of control)
<b>EHT</b>	69	not detected	82	270
<b>VAT</b>	83	not detected	82	380


The results have shown that the water extract of the medicinal plant *Epilobium hirsutum* L. caused 31% and 18% decrease in CYP24A1 and CYP27B1 protein expressions, respectively. As indicated before, CYP24A1 works for inactivation of vitamin D<sub>3</sub> compounds while CYP27B1 involves in the activation of vitamin D. Treatment of *Epilobium hirsutum* L. caused the same effect on these reverse acting enzymes. It can be explained by the presence of several phytochemicals each of which can interfere with different metabolic pathways. These phytochemicals include steroids ( $\beta$ -sitosterol and its esters), tannins (gallic, protocatechuic, ellagic and p-coumaric acids) and flavonoids (in particular myricetin, isomyricetin, and quercetin). To detect the specific active metabolite which modulates the protein expression of CYP24A1 or CYP27B1, isolation and characterization of these pharmacologically active compounds of *Epilobium hirsutum* L. must be done.

*Epilobium hirsutum* L. caused 2.7 fold increase in mRNA expression of CYP27B1 with respect to controls and normalized with GAPDH (Glyceraldehyde 3-phosphate



dehydrogenase) expression as an internal reference. It appears that the attempted increase of CYP27B1 mRNA expression does not translate into an appropriate increase of CYP27B1 protein levels. Post-transcriptional regulations generally cause low correlation between protein and mRNA level. For most of the eukaryotic organisms, variations in mRNA level explain only half or less of variation of protein abundance. Transcription, decay of mRNA, translation and degradation of the proteins are the main points which determine the steady state protein concentration even their relative contributions for the final protein amount in eukaryotes are mostly unknown (Vogel *et al.*, 2010). The negative correlation between mRNA and protein level is currently unknown, but there are some possible explanations. It might be due to possible microRNA (miRNA) regulation or reduced translation efficiency, probably through a block of the protein translation machinery. miRNAs are small, noncoding RNA molecules which involves in regulation of gene expression especially in animals. It is predicted that miRNAs control more than 60% of protein coding gene activity without affecting the mRNA stability (Brodersen *et al.*, 2008; Friedman *et al.*, 2009; Lanet *et al.*, 2009). miRNA can function either in inhibition of target mRNA translation or deadenylation and degradation of target mRNAs (Fabian *et al.*, 2010). Since mRNA expression of CYP27B1 was detected by qRT-PCR technique as described in Materials & Methods part of the present study, miRNA would probably act through the inhibition of mRNA translation without degradation. This inhibition occurs through either initiation block or post-initiation block as described by Fabian *et al.*, 2010 and illustrated in Figure 4.1. In initiation blockage, miRNA induced silencing complex (miRISC) can inhibit translation by acting as a repressor of cap recognition and prevent binding of 40S subunit or act as 60S antagonist and prevent joining of 60S subunit. For post-initiation blockage, miRISC inhibits ribosomal elongation by making ribosome to drop-off. Also, it can cause proteolysis of the newly formed polypeptides (Fabian *et al.*, 2010). Also, protein degradation process affects the protein abundance. Ubiquitination and then degradation of target proteins involve in regulation of protein abundance. E3 ubiquitin ligases recognize the signals on target proteins and provide attachment of poly-ubiquitin

chain. Then, proteasomes involve in degradation of these ubiquitinated proteins (Vogel *et al.*, 2010).



**Figure 4. 1** Schematic diagram of miRNA-mediated translational repression (Fabian *et al.*, 2010).

The effect of *Epilobium hirsutum* L. as well as *Viscum album* L. on mRNA expression of CYP24A1 couldn't be observed, because CYP24A1 mRNA was almost undetectable in liver. These negative mRNA expression findings may propose the followings. mRNA of CYP24A1 can be degraded too fast to reliably be tracked due to extremely short half-life or extracellular stimuli and viral infections and proteins found in the liver can have much longer life spans. It was shown that human CYP24A1 mRNA is under post-transcriptional miRNA regulation by miR-125b (Komagata *et al.*, 2009). This miRNA regulation may occur through the degradation of target mRNAs, so we couldn't observe the mRNA of CYP24A1 in the liver. However, further studies must be carried out to understand the exact mechanism of miR-125b. Undetectable level of CYP24A1 mRNA level can also be explained by the presence of mRNA instability determinants. Some sequence elements found in mRNA decide the half-life of mRNA. While some of these determinants promote stabilization of mRNA, the other can involve in rapid mRNA decay. All of these determinants can be present in the 5'- untranslated region (5'-UTR), the coding region, and the 3'- untranslated region (3'-UTR) which require RNA-binding proteins or small non-coding RNAs to exert their effects.

Experimental results have demonstrated that *Viscum album* L. caused 17% and 18% decrease in CYP24A1 and CYP27B1 protein expressions, respectively. As indicated before, CYP24A1 and CYP27B1 work for inactivation and activation of vitamin D, respectively. Treatment of *Viscum album* L. caused the same effect on these reverse acting enzymes. It can be explained by the presence of several phytochemicals each of which can interfere with different metabolic pathways. These phytochemicals include phenylpropanes, caffeic acids, flavonoids, alkaloids, triterpenes, stigmasterol, lectins and viscotoxins. To detect the specific active metabolites which modulate the protein expression of CYP24A1 or CYP27B1, isolation and characterization of these pharmacologically active compounds from *Viscum album* L. must be done.

*Viscum album* L. also caused 3.8 fold increase in mRNA expression of CYP27B1 with respect to controls and normalized with GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) expression as an internal reference. Increased CYP27B1 mRNA level is

uncoupled from protein synthesis and that CYP27B1 protein level in the liver is in fact reduced by the treatment of *Viscum album* L. This inverse relationship between mRNA and protein level might be probably due to miRNA regulation or reduced translation efficiency, as described previously in the effect of *Epilobium hirsutum* L. treatment.

In the present study, only one subspecies of *Viscum album*, *Viscum album* L. subsp. *austriacum* (Wiesb.) Vollmann, was used as plant material. However, the other two *Viscum* subspecies also merit further studies for the evaluation of the comparative effects of these subspecies.

In conclusion, the results of this study showed that water extracts of medicinal plants *Epilobium hirsutum* L. and *Viscum album* L. can modulate the vitamin D<sub>3</sub> metabolism by changing the expression of protein and mRNA of CYP24A1 and CYP27B1. However, both CYP24A1 and CYP27B1 enzymes have different expression levels on different tissues and different species, further studies are required to determine the effects of these plants on different organs as well as different animal models and humans. Also, the isolation and characterization of pharmacologically active compounds from these medicinal plants should be performed to verify the specific compound responsible for the change in protein expression of CYP24A1 as well as both mRNA and protein expression of CYP27B1 enzyme.

## CHAPTER 5

### CONCLUSION

In this present study, *in vivo* effects of medicinal plants *Epilobium hirsutum* L. (Onagraceae, hairy willow herb) and *Viscum album* L. (Loranthaceae, European mistletoe) on rat liver mitochondrial 24-hydroxylase (CYP24A1) and 1 $\alpha$ -hydroxylase (CYP27B1) protein and mRNA expressions were demonstrated for the first time.

These medicinal plants were collected from unpolluted stream beds and their water extracts were obtained. 37.5 mg *Epilobium hirsutum* L./kg body weight/day was intraperitoneally (i.p) injected to 25 Wistar albino rats (*Rattus norvegicus*) for 9 days; 10 mg *Viscum album* L. (subspecies growing on pine trees-subsp. *austriacum* (Wiesb.) Vollmann) /kg body weight/day was injected i.p to 15 rats for 9 days; and 11 animals were used as control group.

*Epilobium hirsutum* L. injection to rats caused 31% decrease in liver mitochondrial CYP24A1 protein expression ( $p < 0.0001$ ). In addition, 18% decrease in liver CYP27B1 protein expression ( $p < 0.05$ ) was observed when animals treated with the same dose of water extract of epilobium. *Epilobium hirsutum* L. caused 2.7 fold increase in mRNA expression of CYP27B1 with respect to controls and normalized with GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) expression as an internal reference ( $p < 0.005$ ). The effect of *Epilobium hirsutum* L. on mRNA expression of CYP24A1 could not be observed, because CYP24A1 mRNA was almost undetectable in liver.

*Viscum album* L. caused 17% decrease in rat liver mitochondrial CYP24A1 protein expression ( $p < 0.05$ ). Injection of water extract of *Viscum album* L. to rats led to 18% decrease in CYP27B1 protein expression ( $p < 0.05$ ). *Viscum album* L. caused 3.8 fold increase in mRNA expression of CYP27B1 with respect to controls and normalized with GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) expression as an internal reference ( $p < 0.005$ ). However, the effect of *Viscum album* L. on mRNA expression of CYP24A1 could not be observed since CYP24A1 mRNA was almost undetectable in liver.

The results of the present study showed that the medicinal plants *Epilobium hirsutum* L. and *Viscum album* L. can have regulatory effects on CYP24A1 and CYP27B1 protein and mRNA expressions. Since both CYP24A1 and CYP27B1 enzymes have different expression levels on different tissues and different species, further studies are required to determine the effects of these plants on different organs as well as different animal models and humans. In addition, these two medicinal plants have several phytochemicals and therefore each of these active compounds can modulate CYP24A1 and CYP27B1 expressions differently. For future perspective, isolation and characterization of pharmacologically active compounds from these medicinal plants should be performed. Therefore, the specific compounds which modulate the protein and mRNA expressions of CYP24A1 and CYP27B1 enzymes can be investigated. Furthermore, effects of these medicinal plants can also be studied in disease states related with vitamin D metabolism.

## REFERENCES

- Abe, E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K., Yamazaki, T., Yoshiki, S., et al. (1981). Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D<sub>3</sub>. *Proceedings of the National Academy of Sciences of the United States of America*, 78(8), 4990–4994.
- Abou-Samra, A. B., Jüppner, H., Kong, X. F., Schipani, E., Iida-Klein, A., Karga, H., Urena, P., et al. (1994). Structure, function, and expression of the receptor for parathyroid hormone and parathyroid hormone-related peptide. *Advances In Nephrology From The Necker Hospital*, 23, 247–264.
- Adali, O., Abu-Baker, T., & Arinç, E. (1996). Immunochemical and sub-structural characterization of sheep lung cytochrome P450LgM2. *The international journal of biochemistry cell biology*, 28(3), 363–372.
- Adali, O. & Arinc, E. (1990). Electrophoretic, spectral, catalytic and immunochemical properties of highly purified cytochrome P-450 from sheep lung. *International Journal of Biochemistry*, 22(12), 1433–1444.
- Annalora, A. J., Goodin, D. B., Hong, W.-X., Zhang, Q., Johnson, E. F., & Stout, C. D. (2010). Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. *Journal of Molecular Biology*, 396(2), 441–451.
- Arinc, E., Hanukoglu, I., Sen, A., & Adali, O. (1995). Tissue- and species-dependent expression of sheep lung microsomal cytochrome P4502B(LgM2). *Biochemistry and molecular biology international*, 37(6), 1121–1126.

- Arinc, E., Adali, O., & Gencler-Ozkan, A. M. (2000). Stimulation of aniline, p - nitrophenol and N -nitrosodimethylamine metabolism in kidney by pyridine pretreatment of rabbits. *Archives of Toxicology*, 74(9), 527–532. doi:10.1007/s002040000164
- Arinc E., Arslan S., Bozcaarmutlu A. and Adali O. (2007) Effects of diabetes on rabbit kidney and lung CYP2E1 and CYP2B4 expression and drug metabolism and potentiation of carcinogenic activity of N-nitrosodimethylamine in kidney and lung. *Food and Chemical Toxicology*, 45, 107-118.
- Bai, X.-Y., Miao, D., Goltzman, D., & Karaplis, A. C. (2003). The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. *The Journal of Biological Chemistry*, 278(11), 9843–9849.
- Balick, M. J., & Cox, P. A. (1996). Plants, people, and culture: the science of ethnobotany. *Peace Research* (Vol. 32, p. 92). Scientific American Library.
- Bar, A., Shani, M., Fullmer, C. S., Brindak, M. E., & Striem, S. (1990). Modulation of chick intestinal and renal calbindin gene expression by dietary vitamin D3, 1,25-dihydroxyvitamin D3, calcium and phosphorus. *Molecular and Cellular Endocrinology*, 72(1), 23–31.
- Barakat, H., Hussein, S., Marzouk, M., & Merfort, I. (1997). Polyphenolic metabolites of *Epilobium hirsutum*. *Phytochemistry*, 46(6).
- Barlow, B. A. (1987). Mistletoes, *Biologist*. 34, 261-269.
- Bartram, T. (1998) *Bartram's Encyclopedia of Herbal Medicine*. London, Constable and Robinson.



- Battinelli, L., Tita, B., Evandri, M. G., & Mazzanti, G. (2001). Antimicrobial activity of *Epilobium* spp. extracts. *Farmaco (Società chimica italiana : 1989)*, 56(5-7), 345–8.
- Baytop, T. (1999) *Therapy with Medicinal Plants in Turkey (Past and Present)*, Second edition, Nobel Medicine Publication.
- Black, S. D., & Coon, M. J. (1987). P-450 cytochromes: structure and function. *Advances in Enzymology and Related Areas of Molecular Biology*, 60, 35–87.
- Brenza, H. L., & DeLuca, H. F. (2000). Regulation of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. *Archives of Biochemistry and Biophysics*, 381(1), 143–52. doi:10.1006/abbi.2000.1970
- Brodersen, P., Sakvarelidze-Achard, L., Bruun-Rasmussen, M., Dunoyer, P., Yamamoto, Y. Y., Sieburth, L., & Voinnet, O. (2008). Widespread translational inhibition by plant miRNAs and siRNAs. *Science*, 320(5880), 1185–1190.
- Burger, A.M., Mengs, U., Schüler, J.B., et al., 2001. Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. *Anticancer Research* 21, 1965–1968.
- Büssing, A., & Schietzel, M. (1999). Apoptosis-inducing properties of *Viscum album* L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. *Anticancer research*, 19(1A), 23–28.
- Cantley, L. K., Russell, J., Lettieri, D., & Sherwood, L. M. (1985). 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. *Endocrinology*, 117(5), 2114–2119.

- Chan, Y.-L., McKay, C., Dye, E., & Slatopolsky, E. (1986). The effect of 1,25 dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. *Calcified Tissue International*, 38(1), 27–32. doi:10.1007/BF02556591
- Coleman, M. (2005). How Phase I Systems Metabolize Substrates. *Human Drug Metabolism* (pp. 24–26). John Wiley & Sons Ltd.
- Committee for Veterinary Medicinal Products Viscum album Summary Report*. (2000). (pp. 1–2).
- Cooke, N. E., & Haddad, J. G. (1989). Vitamin D binding protein (Gc-globulin). *Endocrine Reviews*, 10(3), 294–307.
- Cooke, N. E., McLeod, J. F., Wang, X. K., & Ray, K. (1991). Vitamin D binding protein: genomic structure, functional domains, and mRNA expression in tissues. *The Journal of steroid biochemistry and molecular biology*, 40(4-6), 787–793.
- Cross, H. S., Kállay, E., Lechner, D., Gerdenitsch, W., Adlercreutz, H., & Armbrecht, H. J. (2004). Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. *The Journal of nutrition*, 134(5), 1207S–1212S.
- Dardenne, O., Prud'homme, J., Arabian, A., Glorieux, F. H., & St-Arnaud, R. (2001). Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. *Endocrinology*, 142(7), 3135–3141.
- Darwish, H. M., & DeLuca, H. F. (1996). Analysis of binding of the 1,25-dihydroxyvitamin D<sub>3</sub> receptor to positive and negative vitamin D response elements. *Archives of Biochemistry and Biophysics*, 334(2), 223–234.

- Davis, P.H. *Flora of Turkey and the East Aegean Islands*, Vol. 4, Edinburgh Univ. Press, Edinburgh. (1972).
- Davis, P.H. *Flora of Turkey and the East Aegean Islands*, Vol. 7, Edinburgh Univ. Press, Edinburgh. (1982).
- Deliorman, D., Calis, I., Ergun, F., 2001a. A new acyclic monoterpene glucoside from *Viscum album* ssp. *Album*. *Fitoterapia*, 72, 101–105. 443
- Deliorman, D., Ergun, F., Sener, B., Palittapongarnpim, P., 2001b. Evaluation of antibacterial activity of *Viscum album* subspecies. *Pharmaceutical Biology*, 39, 445 381–385.
- Ey, P. L. and Ashman, L. K. (1986). The use of alkaline phosphatase-conjugated anti-immunoglobulin with immunoblots for determining the specificity of monoclonal antibodies to protein mixtures. *Methods in Enzymology*, 121, 497-509.
- Fabian, M. R., Sonenberg, N., & Filipowicz, W. (2010). Regulation of mRNA translation and stability by microRNAs. *Annual Review of Biochemistry*, 79(1), 351–379.
- Farhan, H., & Cross, H. S. (2002). Transcriptional inhibition of CYP24 by genistein. *Annals Of The New York Academy Of Sciences*, 973, 459–462.
- Franz, H. (1986). Mistletoe lectins and their A and B chains. *Oncology*, 43 Suppl 1 (suppl. 1), 23–34.
- Friedman, P. A., & Gesek, F. A. (1993). Vitamin D3 accelerates PTH-dependent calcium transport in distal convoluted tubule cells. *American Journal of Physiology*, 265(4 Pt 2), F300–F308.
- Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. *Genome Research*, 19(1), 92–105.

- Fu, G. K., Lin, D., Zhang, M. Y., Bikle, D. D., Shackleton, C. H., Miller, W. L., & Portale, A. A. (1997). Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. *Molecular endocrinology Baltimore Md*, 11(13), 1961–1970.
- Garabedian, M., Holick, M. F., Deluca, H. F., & Boyle, I. T. (1972). Control of 25-Hydroxycholecalciferol Metabolism by Parathyroid Glands. *Proceedings of the National Academy of Sciences of the United States of America*, 69(7), 1673–1676.
- Gençler-Ozkan, A. M., Koyuncu, M. (2005) Traditional Medicinal Plants Used in Pınarbaşı Area (Kayseri-Turkey). *Turkish Journal of Pharmaceutical Sciences*, 2(2), 63-82.
- Gruenwald, J., Brendler, T., & Jaenicke, C. (2000). *PDR for Herbal*. New Jersey: Medical Economics Company.
- Guengerich P. (2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. *Chemical Research in Toxicology*, 14, 611-650.
- Gupta, G., Kazmi, I., Afzal, M., Rahman, M., Saleem, S., Ashraf, M. S., Khusroo, M. J., et al. (2012). Sedative, antiepileptic and antipsychotic effects of *Viscum album* L. (Loranthaceae) in mice and rats. *Journal of ethnopharmacology*, 1–7. doi:10.1016/j.jep.2012.03.013
- Hahn, C. N., Kerry, D. M., Omdahl, J. L., & May, B. K. (1994). Identification of a vitamin D responsive element in the promoter of the rat cytochrome P450(24) gene. *Nucleic Acids Research*, 22(9), 1774–1781.
- Hegde, P., Maddur, M.S., Friboulet, A., Bayry, J., Kaveri, S.V., 2011. *Viscum album* exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. *PLoS One*, 6, 1–7.

- Henry, H. L., Dutta, C., Cunningham, N., Blanchard, R., Penny, R., Tang, C., Marchetto, G., et al. (1992). The cellular and molecular regulation of 1,25(OH)<sub>2</sub>D<sub>3</sub> production. *The Journal of steroid biochemistry and molecular biology*, *41*(3-8), 401–407.
- Henry, H. L., & Luntao, E. M. (1989). Interactions between intracellular signals involved in the regulation of 25-hydroxyvitamin D<sub>3</sub> metabolism. *Endocrinology*, *124*(5), 2228–2234.
- Inoue, Y., Segawa, H., Kaneko, I., Yamanaka, S., Kusano, K., Kawakami, E., Furutani, J., et al. (2005). Role of the vitamin D receptor in FGF23 action on phosphate metabolism. *The Biochemical journal*, *390*(Pt 1), 325–331.
- Ivancheva, S., Manolova, N., Serkedjieva, J., Dimov, V., & Ivanovska, N. (1992). Polyphenols from Bulgarian medicinal plants with anti-infectious activity. *Basic Life Sciences*, *59*, 717-728.
- Jones, G., Strugnell, S. A., & DeLuca, H. F. (1998). Current understanding of the molecular actions of vitamin D. *Physiological Reviews*, *78*(4), 1193–1231.
- Jordan, E., & Wagner, H. (1986). Structure and properties of polysaccharides from *Viscum album* (L.). *Oncology*, *43 Suppl 1*, 8–15.
- Kerry, D. M., Dwivedi, P. P., Hahn, C. N., Morris, H. A., Omdahl, J. L., & May, B. K. (1996). Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D<sub>3</sub> 24-hydroxylase (CYP24) promoter. *The Journal of Biological Chemistry*, *271*(47), 29715–29721.
- Kienle, G. S., & Kiene, H. (2010). Review article: Influence of *Viscum album* L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. *Integrative cancer therapies*, *9*(2), 142-57. doi:10.1177/1534735410369673

- Kiss, A. K., Bazylko, A., Filipek, A., Granica, S., Jaszewska, E., Kiarszys, U., Kośmider, A., et al. (2011). Oenotherin B's contribution to the anti-inflammatory and antioxidant activity of *Epilobium* sp. *Phytomedicine international journal of phytotherapy and phytopharmacology*, 18(7), 557–560.
- Kitanaka, S., Takeyama, K., Murayama, A., Sato, T., Okumura, K., Nogami, M., Hasegawa, Y., et al. (2002). Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. *The New England Journal of Medicine*, 338(2), 653–661.
- Komagata, S., Nakajima, M., Takagi, S., Mohri, T., & Taniya, T. (2009). Human CYP24 Catalyzing the Inactivation of Calcitriol Is Post- Transcriptionally Regulated by miR-125b, 76(4), 702–709. doi:10.1124/mol.109.056986.in
- Kuijt J. 1990. Correlations in the germination pattern of Santalaceae and other mistletoes. In: Bass P, K Kalkman and R Geesink (eds), *Plant Diversity of Malaysia*. Proceedings of the Flora Malaysian Symposium Commemorating Prof. Dr. C.G.G.J. van Steenis. The Netherlands: Kluwer Academic Publisher. p 63–72.
- Kähkönen, M. P., Hopia, A. I., Vuorela, H. J., Rauha, J. P., Pihlaja, K., Kujala, T. S., & Heinonen, M. (1999). Antioxidant activity of plant extracts containing phenolic compounds. *Journal of Agricultural and Food Chemistry*, 47(10), 3954–3962.
- Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of head of bacteriophage T4. *Nature*, 227, 680-685.
- Lanet, E., Delannoy, E., Sormani, R., Floris, M., Brodersen, P., Crete, P., Voinnet, O., et al. (2009). Biochemical Evidence for Translational Repression by Arabidopsis MicroRNAs. *Plant Cell*, 21(6), 1762–1768.
- Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H. S., Jüppner, H., et al. (2004). Transgenic mice expressing fibroblast growth factor 23

under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. *Endocrinology*, *145*(7), 3087–3094.

Li, Y. C., Pirro, a E., & Demay, M. B. (1998). Analysis of vitamin D-dependent calcium-binding protein messenger ribonucleic acid expression in mice lacking the vitamin D receptor. *Endocrinology*, *139*(3), 847–51.

Liu, S. M., Koszewski, N., Lupez, M., Malluche, H. H., Olivera, A., & Russell, J. (1996). Characterization of a response element in the 5'-flanking region of the avian (chicken) PTH gene that mediates negative regulation of gene transcription by 1,25-dihydroxyvitamin D<sub>3</sub> and binds the vitamin D<sub>3</sub> receptor. *Molecular endocrinology Baltimore Md*, *10*(2), 206–215.

Livak, K. J., & Schmittgen, T. D. (2001). Analysis of Relative Gene Expression Data Using Real- Time Quantitative PCR and the  $2^{\Delta\Delta Ct}$  Method. *Gene Expression*, *408*, 402–408. doi:10.1006/meth.2001.1262

Lobaugh, B., Garner, S. C., Lovdal, J. A., Boass, A., & Toverud, S. U. (1993). Parathyroidectomy abolishes the increase of renal 25-hydroxyvitamin D-1 alpha-hydroxylase in lactating rats. *American Journal of Physiology*, *264*(6 Pt 1), E981–E985.

Lowry, O., Rosebrough, N., Farr, A., & Randall, R. (1951). Protein measurement with the Folin phenol reagent. *Journal of Biological Chemistry*, *193*(1), 265-275.

Ly, L. H., Zhao, X. Y., Holloway, L., & Feldman, D. (1999). Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D<sub>3</sub> to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. *Endocrinology*, *140*(5), 2071–2076.

- Makin, G., Lohnes, D., Byford, V., Ray, R., & Jones, G. (1989). Target cell metabolism of 1,25-dihydroxyvitamin D<sub>3</sub> to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. *The Biochemical Journal*, 262(1), 173–180.
- Masuda, S., Strugnell, S., Calverley, M. J., Makin, H. L., Kremer, R., & Jones, G. (1994). In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. *The Journal of Biological Chemistry*, 269(7), 4794–4803.
- Masuda, Sonoko, Strugnell, S. A., Knutson, J. C., St-Arnaud, R., & Jones, G. (2006). Evidence for the activation of 1alpha-hydroxyvitamin D<sub>2</sub> by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D<sub>2</sub> and 1alpha,25-dihydroxyvitamin D<sub>2</sub>. *Biochimica et Biophysica Acta*, 1761(2), 221–234.
- Matsumoto, T., Igarashi, C., Takeuchi, Y., Harada, S., Kikuchi, T., Yamato, H., & Ogata, E. (1991). Stimulation by 1,25-dihydroxyvitamin D<sub>3</sub> of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. *Bone*, 12(1), 27–32.
- Matsumoto, T., Ikeda, K., Morita, K., Fukumoto, S., Takahashi, H., & Ogata, E. (1987). Blood Ca<sup>2+</sup> modulates responsiveness of renal 25(OH)D<sub>3</sub>-1 alpha-hydroxylase to PTH in rats. *American Journal of Physiology*, 253(5 Pt 1), E503–E507.
- Mckinnon, R. A., Sorich, M. J., & Ward, M. B. (2008). Cytochrome P450 Part 1 : Multiplicity and Function, *Journal of Pharmacy Practice and Research Volume*, 38(1), 55–57.
- Mitchell, W. (2003). *Plant medicines in practice*. Edinburgh: Churchill Livingstone.
- Muindi, J. R., Yu, W.-D., Ma, Y., Engler, K. L., Kong, R.-X., Trump, D. L., & Johnson, C. S. (2010). CYP24A1 inhibition enhances the antitumor activity of calcitriol. *Endocrinology*, 151(9), 4301–4312.



- Murayama, A., Takeyama, K., Kitanaka, S., Kodera, Y., Hosoya, T., & Kato, S. (1998). The promoter of the human 25-hydroxyvitamin D<sub>3</sub> 1 alpha-hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 alpha,25(OH)<sub>2</sub>D<sub>3</sub>. *Biochemical and Biophysical Research Communications*, 249(1), 11–16.
- Murray T. M. (1995), *The Healing Power of Herbs*, 2nd ed. Prima, Rocklin, CA, pp. 253-260.
- Nebert, D. (1987). P450 genes: structure, evolution, and regulation. *Annual Review of Biochemistry*, 56, 945–993.
- Nelson, D. R. (2009). The Cytochrome P450 Homepage. *Human Genomics*, 4, 59-65.
- Newall C. A., Anderson L. A., and Phillipson J. D. (1996). *Herbal Medicines*. Pharmaceutical Press, London, pp. 193-196.
- Norman, A., & Henry, H. (2007). Vitamin D. *Handbook of Vitamins, Fourth Edition*. CRC Press. doi:doi:10.1201/9781420005806.ch2
- Ofem, O.E., Eno, A.E., Imoru, J., Nkanu, E., Unoh, F., Ibu, J.O., 2007. Effect of crude aqueous leaf extract of *Viscum album* (mistletoe) in hypertensive rats. *Indian Journal of Pharmacology*, 39, 15–19.
- Ohyama, Y., Ozono, K., Uchida, M., Shinki, T., Kato, S., Suda, T., Yamamoto, O., et al. (1994). Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D<sub>3</sub> 24-hydroxylase gene. *The Journal of Biological Chemistry*, 269(14), 10545–50.
- Ohyama, Y., Ozono, K., Uchida, M., Yoshimura, M., Shinki, T., Suda, T., & Yamamoto, O. (1996). Functional assessment of two vitamin D-responsive

- elements in the rat 25-hydroxyvitamin D<sub>3</sub> 24-hydroxylase gene. *The Journal of Biological Chemistry*, 271(48), 30381–30385.
- Ohyama, Y., & Yamasaki, T. (2004). Eight cytochrome P450s catalyze vitamin D metabolism. *Front Biosci*, 9, 3007–3018.
- Omdahl, J. L., Morris, H. A., & May, B. K. (2002). Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. *Annual Review of Nutrition*, 22, 139–166.
- Omura, T., & Sato, R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. *The Journal of Biological Chemistry*, 239(7), 2370–2378.
- Orhan, D.D., Aslan, M., Sendogdu, N., Ergun, F., Yesilada, E., 2005. Evaluation of the hypoglycemic effect and antioxidant activity of three *Viscum album* subspecies (European mistletoe) in streptozotocind diabetic rats. *Journal of Ethnopharmacology*, 98, 95–102.
- Panda, D. K., Miao, D., Tremblay, M. L., Sirois, J., Farookhi, R., Hendy, G. N., & Goltzman, D. (2001). Targeted ablation of the 25-hydroxyvitamin D 1alpha - hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. *Proceedings of the National Academy of Sciences of the United States of America*, 98(13), 7498–7503.
- Perwad, F., Zhang, M. Y. H., Tenenhouse, H. S., & Portale, A. A. (2007). Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. *American journal of physiology Renal physiology*, 293(5), F1577–F1583.

- Posner, G. H., Helvig, C., Cuerrier, D., Collop, D., Kharebov, A., Ryder, K., Epps, T., et al. (2010). Vitamin D analogues targeting CYP24 in chronic kidney disease. *The Journal of Steroid Biochemistry and Molecular Biology*, *121*(1-2), 13–19.
- Prosser, D. E., & Jones, G. (2004). Enzymes involved in the activation and inactivation of vitamin D. *Trends in biochemical sciences*, *29*(12), 664–73. doi:10.1016/j.tibs.2004.10.005
- Reddy, G. S., & Tserng, K. Y. (1989). Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D<sub>3</sub> through C-24 oxidation pathway. *Biochemistry*, *28*(4), 1763–1769.
- Reinhardt, T. A., & Horst, R. L. (1990). Parathyroid hormone down-regulates 1,25-dihydroxyvitamin D receptors (VDR) and VDR messenger ribonucleic acid in vitro and blocks homologous up-regulation of VDR in vivo. *Endocrinology*, *127*(2), 942–948.
- Rickard, D. J., Kazhdan, I., & Leboy, P. S. (1995). Importance of 1,25-dihydroxyvitamin D<sub>3</sub> and the nonadherent cells of marrow for osteoblast differentiation from rat marrow stromal cells. *Bone*, *16*(6), 671–678.
- Roman, I., Rusu, M., & Puica, C. (2010). Citotoxic effects of three species of *Epilobium* (Onagraceae) herbal extracts in rats, *20*(1), 19–23.
- Sakaki, T., Kagawa, N., & Yamamoto, K. (2005). Metabolism of vitamin D<sub>3</sub> by cytochromes P450. *Front Biosci*, *45*(5), fmiii–fmiv. doi:10.1002/mus.23403
- Sakaki, T., Sawada, N., Komai, K., Shiozawa, S., Yamada, S., Yamamoto, K., Ohyama, Y., et al. (2000). Dual metabolic pathway of 25-hydroxyvitamin D<sub>3</sub> catalyzed by human CYP24. *The Federation of European Biochemical Societies Journal*, *267*(20), 6158–6165.

- Schenkman, J. B., & Cinti, D. L. (1978). Preparation of microsomes with calcium. *Methods in Enzymology*, 52, 83-89.
- Schreiner, M., & Huyskens-Keil, S. (2006). Critical Reviews in Plant Sciences  
Phytochemicals in Fruit and Vegetables: Health Promotion and Postharvest  
Elicitors Phytochemicals in Fruit and Vegetables: Health Promotion and  
Postharvest Elicitors. *Critical Reviews in Plant Sciences*, 25(3), 267–278.  
doi:10.1080/07352680600671661
- Schuster, I., Egger, H., Bikle, D., Herzig, G., Reddy, G. S., Stuetz, A., Stuetz, P., et al. (2001). Selective inhibition of vitamin D hydroxylases in human keratinocytes. *Steroids*, 66(3-5), 409–422.
- Sen, A., & Kirikbakan, A. (2004). Biochemical characterization and distribution of glutathione S-transferases in leaping mullet (*Liza saliens*). *Biochemistry Biokhimiia*, 69(9), 993-1000.
- Shankar, V. N., Propp, A. E., Schroeder, N., Surber, B. W., Makin, H. L., & Jones, G. (2001). In vitro metabolism of 19-nor-1 $\alpha$ , 25-(OH)<sub>2</sub>D<sub>2</sub> in cultured cell lines: inducible synthesis of lipid- and water-soluble metabolites. *Archives of Biochemistry and Biophysics*, 387(2), 297–306.
- Shinki, T., Jin, C. H., Nishimura, A., Nagai, Y., Ohyama, Y., Noshiro, M., Okuda, K., et al. (1992). Parathyroid hormone inhibits 25-hydroxyvitamin D<sub>3</sub>-24-hydroxylase mRNA expression stimulated by 1  $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> in rat kidney but not in intestine. *The Journal of Biological Chemistry*, 267(19), 13757–13762.
- Shinki, T., Ueno, Y., & DeLuca, H. (1999). Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D<sub>3</sub>-1 $\alpha$ -hydroxylase gene in normocalcemic rats. *Proceedings of the National Academy of Sciences of the United States of America*, 96(14), 8253–8258.

- Simsek, I., Aytekin, F., Yesilada, E., Yıldırım, Ş. (2004) An ethnobotanical survey of the Beypazarı, Ayas and Gudul district towns of Ankara Province (Turkey). *Economic Botany*, 58, 705-720.
- St-Arnaud, R. (2011). CYP24A1: Structure, Function, and Physiological Role. *Vitamin D, Third edition*. Academic Press. doi:10.1016/B978-0-12-381978-9.10001-0
- St-Arnaud, R., Messerlian, S., Moir, J. M., Omdahl, J. L., & Glorieux, F. H. (1997). The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. *Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research*, 12(10), 1552–1559.
- Stuckey, R. L. 1970. Distributional history of *Epilobium hirsutum* (Great Hairy Willow-herb) in North America. *Rhodora*, 72(790), 164-181.
- Suda, T., Udagawa, N., Nakamura, I., Miyaura, C., & Takahashi, N. (1995). Modulation of osteoclast differentiation by local factors. *Bone*, 17(2 Suppl), 87S–91S.
- Sutton, A. L. M., & MacDonald, P. N. (2003). Vitamin D: more than a “bone-a-fide” hormone. *Molecular Endocrinology Baltimore Md*, 17(5), 777–791.
- Szabo, A., Merke, J., Beier, E., Mall, G., & Ritz, E. (1989). 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> inhibits parathyroid cell proliferation in experimental uremia. *Kidney International*, 35(4), 1049–1056.
- Tanaka, H., Abe, E., Miyaura, C., Kuribayashi, T., Konno, K., Nishii, Y., & Suda, T. (1982). 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). *The Biochemical Journal*, 204(3), 713–9.
- Tompkins, A. (2009). *Viscum album*, European Mistletoe Effects on Breast and Gynecological Cancers. *October*, 1–5.

- Towbin, H., Staehelin, T., & Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proceedings of the National Academy of Sciences*, 76(9), 4350-4354.
- Tucker, G., Gagnon, R. E., & Haussler, M. R. (1973). Vitamin D 3 -25-hydroxylase: tissue occurrence and apparent lack of regulation. *Archives of Biochemistry and Biophysics*, 155(1), 47-57.
- Varghese, S., Lee, S., Huang, Y. C., & Christakos, S. (1988). Analysis of rat vitamin D-dependent calbindin-D28k gene expression. *The Journal of Biological Chemistry*, 263(20), 9776-9784.
- Vattem, D. A., & Shetty, K. (2005). Biological Functionality of Ellagic Acid: a Review. *Journal of Food Biochemistry*, 29(3), 234-266. doi:10.1111/j.1745-4514.2005.00031.x
- Vogel, C., De Sousa Abreu, R., Ko, D., Le, S.-Y., Shapiro, B. A., Burns, S. C., Sandhu, D., et al. (2010). Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. *Molecular Systems Biology*, 6(400), 400.
- Wagner H., Jordan F. B. (1986). Studies on the standardization of mistletoe preparations. *Oncology*, 43, 16-22.
- Wang, J. T., Lin, C. J., Burridge, S. M., Fu, G. K., Labuda, M., Portale, A. A., & Miller, W. L. (1998). Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. *The American Journal of Human Genetics*, 63(6), 1694-1702.
- Weinstein, R. S., Underwood, J. L., Hutson, M. S., & DeLuca, H. F. (1984). Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus. *American Journal of Physiology*, 246(6 Pt 1), E499-E505.

- Weisinger, J. R., Favus, M. J., Langman, C. B., & Bushinsky, D. A. (1989). Regulation of 1,25-dihydroxyvitamin D<sub>3</sub> by calcium in the parathyroidectomized, parathyroid hormone-replete rat. *Journal of bone and mineral research the official journal of the American Society for Bone and Mineral Research*, 4(6), 929–935.
- Werck-Reichhart, D., & Feyereisen, R. (2000). Protein family review Cytochromes P450 : a success story, *Genome Biology*, 1(6), 1–9.
- Wichtl M. and Bisset N. G. (eds.) (1994), Visci herba- Mistletoe herb. In: Herbal Drugs and Phyto-pharmaceuticals. CRC Press, Stuttgart, pp. 534-536.
- Wojdylo, A., Oszmianski, J., & Czemerys, R. (2007). Antioxidant activity and phenolic compounds in 32 selected herbs. *Food Chemistry*, 105(3), 940-949.
- Yamada, S., Nakayama, K., Takayama, H., Shinki, T., Takasaki, Y., & Suda, T. (1984). Isolation, identification, and metabolism of (23S,25R)-25-hydroxyvitamin D<sub>3</sub> 26,23-lactol. A biosynthetic precursor of (23S,25R)-25-hydroxyvitamin D<sub>3</sub> 26,23-lactone. *The Journal of Biological Chemistry*, 259(2), 884–889.
- Yamamoto, M., Kawanobe, Y., Takahashi, H., Shimazawa, E., Kimura, S., & Ogata, E. (1984). Vitamin D deficiency and renal calcium transport in the rat. *Journal of Clinical Investigation*, 74(2), 507–513.
- Yesilada, E., Deliorman, D., Ergun, F., Takaishi, Y., Ono, Y. (1998) Effects of Turkish subspecies of *Viscum album* on macrophage-derived cytokines. *Journal of Ethnopharmacology*, 61, 195-200.
- Yoshida, T., Monkawa, T., Tenenhouse, H. S., Goodyer, P., Shinki, T., Suda, T., Wakino, S., et al. (1998). Two novel 1 $\alpha$ -hydroxylase mutations in French-Canadians with vitamin D dependency rickets type II. *Kidney International*, 54(5), 1437–1443.

- Yucecan, S., Akgun, B., Ciftci, N., Aksoy, C., Tayfur, M., Tasci, N. (1988) Plants used in the treatment of hypertension in the East and Southeast Anatolia. *Journal of Faculty of Pharmacy of Hacettepe University* 8, 25–31.
- Zehnder, D., Bland, R., Williams, M. C., McNinch, R. W., Howie, A. J., Stewart, P. M., & Hewison, M. (2001). Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. *The Journal of Clinical Endocrinology & Metabolism*, 86(2), 888–894.
- Zeldin, D. (2008). Structure, Mechanism, and Regulation of Cytochromes P450. *Molecular and Biochemical Toxicology*, 154–155.
- Zierold, C., Darwish, H. M., & DeLuca, H. F. (1994). Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. *Proceedings of the National Academy of Sciences of the United States of America*, 91(3), 900–902.
- Zierold, C., Darwish, H. M., & DeLuca, H. F. (1995). Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. *The Journal of Biological Chemistry*, 270(4), 1675–1678.
- Zierold, C., Reinholz, G. G., Mings, J. A., Prahl, J. M., & DeLuca, H. F. (2000). Regulation of the porcine 1,25-dihydroxyvitamin D3-24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 and parathyroid hormone in AOK-B50 cells. *Archives of Biochemistry and Biophysics*, 381(2), 323–327.



## APPENDIX A

### APPROVALS OBTAINED FROM ETHICAL COMMITTEE

T.C  
PAMUKKALE ÜNİVERSİTESİ  
HAYVAN DENEYLERİ ETİK KURULU BAŞKANLIĞI

Sayı :B.30.2.PAÜ.0.01.00.00.400-1/08 17.02.2009  
Konu :Çalışma Başvurusu


Sayın;  
Prof. Dr. Alaattin ŞEN  
Fen Edebiyat Fakültesi  
Biyoloji Bölümü  
Öğretim Üyesi

İlgi : 22.01.2009 tarihli başvurunuz.

“Yakı Otunun Ksenobiyotik Metabolizması Üzerine Etkilerinin ve İlaç-Diyet Etkileşim Potansiyelinin Proteomik ve Moleküler Yaklaşımlar ile Aydınlatılması” konulu PAUHDEK-2009/007 no’lu çalışmanız 11.02.2009 tarih ve 02 sayılı toplantımızda görüşülmüş olup,

Çalışmanın yapılmasının Hayvan Deneyleri Etiği açısından uygun olduğuna oy çokluğu ile karar verilmiştir.

Gereğini bilgilerinize rica ederim.

  
Doç. Dr. Vural KÜÇÜKATAY  
Başkan

Not: Ciddi  
İmzalı belge  
Proje çıktıları ile  
gönderilecek.

213/09  
ekin kimya  
www.ekinkimya.com

T.C.  
PAMUKKALE ÜNİVERSİTESİ  
HAYVAN DENeyLERİ ETİK KURUL BAŞKANLIĞI  
TOPLANTI TUTANAĞI

Toplantı Tarihi	11.02.2009	Karar	3
Toplantı Sayısı	2	Toplantı Saati	15:00
Toplantı Günü	Çarşamba	Toplantı Yeri	Dekanlık

**Karar 3-** Fen Edebiyat Fakültesi Biyoloji Bölümü Öğretim üyesi Prof. Dr. Alaattin ŞEN'in yürütücüsü olduğu "Yakı Otunun Ksenobiyotik Metabolizması Üzerine Etkilerinin ve İlaç-Diyet Etkileşim Potansiyelinin Proteomik ve Moleküller Yaklaşımları ile Aydınlatılması" konulu PAUHDEK-2009/007 no'lu çalışması görüşülmüş olup,

Çalışmanın yapılmasının **Hayvan Deneyleri Etiği** açısından uygun olduğuna oy çokluğu ile karar verilmiştir.

Yrd.Doç.Dr.Mustafa KARATEPE

Doç. Dr. Vural KÜÇÜKATAY  
Başkan

Doç.Dr.Çağrı ERGİN	Yrd.Doç.Dr.Mustafa KARATEPE	
Doç.Dr.Yakup KASKA	Doç.Dr.Burhan KABAY	KATILMADI
Yrd.Doç.Dr.Funda BÖLÜKBAŞI HATİP	Uzm.Vet.Hek.Barbaros ŞAHİN	
Dr.Berna TURGUT	Şemsaddin ÖZMEN	

T.C.  
PAMUKKALE ÜNİVERSİTESİ  
HAYVAN DENEYLERİ ETİK KURULU BAŞKANLIĞI

SAYI :B.30.2.PAÜ.0.01.00.00.400-1/25  
KONU :Çalışma Başvurusu

16.05.2008


**İLGİLİ MAKAMA**

**İlgi:** Prof.Dr.Alaattin ŞEN'in 30.04.2008 tarihli başvurusu.




İlgi dilekçe ile başvuran Prof.Dr.Alaattin ŞEN'in "Ülkemizde Tıbbi Bitki Olarak Kullanılan Epilobium hirsutum ve Viscum album Bitkilerinin Tedavi Edivi ve zararlı Etkilerinin ve Etki Mekanizmalarının Moleküler Yaklaşımlar ile Aydınlatılması" konulu PAUHDEK-2008/012 no'lu çalışması 16.05.2008 tarih ve 06 sayılı toplantımızda görüşülmüş olup,

Çalışmanın yapılmasının **Hayvan Deneyleri Etiği açısından uygun olduğuna** oy birliği ile karar verilmiştir.

İş bu belge kişinin isteği üzerine verilmiştir.

  
**Doç. Dr. Vural KÜÇÜKATAY**  
Başkan

**ORTA DOĞU TEKNİK ÜNİVERSİTESİ**  
**HAYVAN DENEYLERİ ETİK KURUL KARARLARI**

<b>KARAR SAYISI : Etik-2009/16</b>	<b>KARAR TARİHİ: 27.08.2009</b>
<p>O.D.T.Ü. Biyoloji Bölümü Öğretim Üyesi Prof. Dr. Orhan ADALI'nın 2009/16 no'lu "Yakıtunun Ksenobiyotik Metabolizması Üzerine Etkilerinin ve İlaç-Diyet Etkileşim Potansiyelinin Proteomik ve Moleküler Yaklaşımlar ile Aydınlatılması" başlıklı araştırma projesinin etik başvurusu değerlendirilmiştir.</p> <p>Etik Kurul'un 27.08.2009 tarihinde yapılan toplantısında, yukarıda adı geçen projenin araştırmadaki deney hayvanlarının tür, sayı ve kullanım amaçlarının ve projenin deney hayvanlarına ilişkin yönlerinin O.D.T.Ü. Hayvan Deneyleri Yerel Etik Kurul Yönergesinde belirtilen "Hayvan Deneyleri ile İlgili Etik İlkeler" dikkate alınarak hazırlandığı saptanmıştır. Bu değerlendirme sonucu çalışmanın 60 adet RAT ile yapılmasının hayvan etiği açısından uygun olduğu oy çokluğu ile onaylanmıştır.</p>	
 Doç. Dr. Ewa (Havva) Doğru Başkan	 Jale Esin Sivil Üye, Başkan Vekili
KATILMADI Prof. Dr. Orhan Adalı Üye	 Prof. Dr. Gülay Özcengiz Üye
 Prof. Dr. İnci Togan Üye	 Prof. Dr. Vasıf Hasırcı Üye
KATILMADI Prof. Dr. Feza Korkusuz Tıp Hekim, Üye	KATILMADI Y. Doç. Dr. Barış Parkan Üye
 Dr. Uğur Göğüş Vet. Hekim, Üye	 Dr. Seçil Cabuk Vet. Hekim, Üye
KATILMADI Av. Neşide Öncül Kurum İçinden Seçilen Hukuk Müşaviri	 Nilgün Egemen Sivil Toplum Kuruluşu Dernek Üyesi